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Chapter 1
Research and Care of Inflammatory Bowel Disease – 
Time for a Gender-Specific Approach?
IntRODUctIOn
No one would argue that men and women differ. The differences between the sexes are obvious 
and affect every aspect of life. The biological grounds for these differences are determined by 
the complementary yet distinct roles of the two sexes in the process of procreation. The success 
of human reproduction is related to the very efficient selection process for the proper genetic 
material that will, after 40 weeks of intense physical investment by the female, result in the birth 
of a healthy progenitor1. This ultimate goal of procreation determines the basic differences 
between male and female biology that presumably functions at the level of every cell. 
In general, each individual’s physiognomy, character, susceptibility to specific diseases 
and life expectancy results from an interaction between genes and the environment. At the 
cellular level, basic differences between the female XX and male XY genotypes leads to a great 
divergence in protein structure that influences a variety of biochemical processes. With such 
divergence at the cellular level, substantial differences are expected at all levels of various 
physiological and patho-physiological processes in males compared with females. This, in turn, 
would be reflected in the sexually dimorphic presentation and phenotype of different diseases, 
and in drug pharmacokinetics and pharmacodynamics as well as subjective perceptions of the 
burden of disease. 
Yet, most medical interventions not related to reproductive organs are conducted in the 
same manner in both men and women. Medical textbooks only include a ‘unisex’ description 
of disease presentation, men and women are unequally represented during drug development 
and testing2, and pharmaco-economic studies using quality of life assessments are still subject 
to important gender biases3. Undoubtedly, every physician creates and uses his/her own 
gender-specific way of working on a daily basis, but without proper evidence-based grounds for 
such an approach. A rather isolated example is in cardiology, where the first report of increased 
mortality in women with coronary heart disease compared with men prompted a thorough 
analysis of the problem, and resulted in the creation of gender-specific guidelines4, 5.
The biological differences between women and men may greatly impact physiological and 
pathophysiological conditions. A main goal of medicine in the twenty-first century, providing 
truly personalized care for each patient, should start with the creation of respective female and 
male concepts of health and disease. To achieve this, each speciality needs to inventory its own 
gender-specific issues that can serve as the basis for further investigation into the contributions 
of gender/sex to disease pathogenesis and its impact on choosing appropriate therapeutic 
strategies.
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GenDeR AnD SeX In HeALtH AnD DISeASe
General considerations and terminology 
During the past two decades, the important influence of gender/sex on the type and 
presentation of some diseases has been put on the research agendas of several health 
organizations6 ,7. Systematic research in this field showed that sex-related differences are present 
at virtually every level of functioning of the human body6. At the level of clinical research, 
these differences are present in the sexual dimorphic prevalence, phenotypes, prognosis, and 
therapy success of a broad range of diseases. Additionally, the influence of gender on health-
related quality of life (HRQOL) and the bias this influence may cause in the cost-effectiveness 
analysis of various therapeutic strategies is being recognized3. These observations pointing out 
the importance of gender/sex in health and disease have prompted further mechanistic studies 
on the cellular and molecular basis of the observed phenomena, but in most cases the sexual 
dimorphic features of the disease are yet to be elucidated. Once the main question, “to what 
extent and how does sex play a role in the pathogenesis of a particular disease?” is answered, 
the development of tailored therapies for men and women can start.
On the other hand, sex differences contribute to variations in biology and can be used as a tool 
for efficiently researching various physiological processes6. Thus, introducing sex systematically 
as one of the variables in experimental design would be valuable, not only for understanding 
the role of sex in a particular biological process, but sex-related differences can also help to 
elucidate the details of the process itself. 
The non-recognition or underestimation of the biological contributions of gender/sex to 
human health is currently subject to active discussion. This discussion resulted in suggestions 
of several regulatory mechanisms that should ensure that gender/sex is taken into account 
at the initiation of experimental or trial designs. The use of unified terminology is one of the 
prerequisites for this process; especially, the terms sex and gender should be used consistently. 
According to the WHO definition, gender refers to “the socially constructed roles, behaviours, 
activities, and attributes that a given society considers appropriate for men and women”, whereas 
sex refers to the biological and physiological characteristics that define men and women7. In 
line with these definitions, the Committee on Understanding the Biology of Sex and Gender 
Differences6 recommends using the term sex to classify males or females according to the 
reproductive organs and functions that derive from the chromosomal complement, and to use 
the term gender to refer to a person’s self-representation as male or female, or how that person 
is responded to by social institutions on the basis of the individual’s gender presentation.
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“‘If health care systems are to respond adequately to problems caused by gender 
inequality, it is not enough to simply ‘add in’ a gender component late in a given project’s 
development. Research, interventions, health system reforms, health education, health 
outreach, and health policies and programmes must consider gender from the beginning. 
Gender is thus not something that can be consigned to ’watchdogs’ in a single office, since 
no one office can possibly involve itself in all phases of an organization’s activities. All health 
professionals must have knowledge and awareness of the ways in which gender affects 
health, so that they may address gender issues wherever appropriate thus rendering their 
work more effective” http://www.who.int/gender/gender_mainstreaming/en/index.html
ROLe OF GenDeR/SeX In InFLAmmAtORY BOWeL DISeASe
INFLAMMATORY BOWEL DISEASE
Inflammatory bowel disease (IBD) is a chronic relapsing inflammatory condition that affects 
the gastrointestinal tract. The disease typically manifests itself in the second and third decade 
of life and persists throughout the individual’s lifetime. It comprises two conditions; Crohn`s 
disease (CD) and ulcerative colitis (UC). The two conditions differ in the localisation and extent 
of inflammation at the mucosal level. The transmural inflammation typical of CD is localised at 
any part of the gastrointestinal tract, whereas superficial inflammation is confined exclusively 
to the large bowel in UC. However, physicians in clinical practice encounter many disorders that 
at presentation and/or through the evolution of the disease cannot be definitely allocated to 
one these categories, and are then designated as unclassified colitis8. Thus, the term IBD refers 
to a large spectrum of inflammatory conditions affecting the gastro-intestinal tract.
The aetiology of IBD is unknown, but the evidence gathered supports the hypothesis that 
the inflammation of the intestinal mucosa results from an ill-directed immune response 
to commensal bacteria in a genetically-susceptible host9. This feature of a problematic co-
existence with autologous intestinal flora takes the aetiological viewpoint that IBD is a unique 
auto-immune condition in which the normal distinction between pathogens and commensals 
is disturbed. Additionally, up to half of IBD patients also have the extra-intestinal manifestations 
of sterile inflammation of joints, skin, uvea, and liver10. These findings complement the view of 
IBD as an autoimmune disorder with an aberrant immune response that is systemic rather than 
confined to the mucosal surface. 
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The presentation of the disease ensues from the inflammation of the gut with typical 
symptoms of diarrhoea, rectal blood loss, abdominal pain, and weight loss. The lack of a thorough 
understanding of the aetio-pathogenesis of the disease in clinical practice is translated into 
the lack of curative treatment. Current therapy for IBD consists mainly of immune suppressive 
medication with all its potential short- and long-term toxicities. Furthermore, this therapy has 
a limited impact on the disease course, probably because it comes late in the pathogenetic 
process, leaving a significant proportion of patients progressing to structural or penetrating 
complications of the disease11.
The epidemiologic reports on IBD vary depending on the population studied; but, generally, 
its incidence seems to be rising. Considering this increasing incidence with the current estimate 
of 2.2 million IBD patients in Europe12, the chronic character of this incurable disease, as well as 
increasing health care costs, IBD represents an important clinical and public health issue. 
 
GENDER
The course of IBD is characterized by flares and remissions, and no existing therapeutic 
approach can cure this disease. Improvement in the health-related quality of life (HRQOL) 
represents a primary goal of therapeutic strategies. In general, women report lower HRQOL, 
regardless of the questionnaire used or the underlying condition13-16, and lower HRQOL in 
women has also consistently been reported in IBD. Female IBD patients have significantly 
reduced HRQOL compared with male patients17,18 and female gender is the strongest predictor 
of low HRQOL in CD19. 
This sexual-dimorphic perception of disease burden can be both gender-related and sex-
determined. With regards to gender, the disease itself as well as medications to treat it cause 
issues typically weighted differentially by women and men. Ostomy, surgical scars, and scaring 
of the perineum resulting from perianal involvement in CD, the use of corticosteroids that are 
associated weight gain, striae, and Cushingoid habitus, are typical body image issues that can 
be perceived more intensely as a problem by women than men. Moreover, as discussed further 
in this chapter (Part Reproduction), IBD strongly interferes with reproduction, be it through 
its potential impact on fertility or because of issues related to the effect of the medication to 
treat IBD on the foetus, the latter typically being a female issue. These intuitive considerations 
have indeed been documented in a report of female IBD patients, who had greater concerns 
than men with regards to feelings about their bodies, attractiveness, feeling alone, and having 
children20. However, reports dealing with gender roles in the determination of the HRQOL are 
scarce, and a detailed analysis of this phenomenon is still lacking. 
The possibility of determining the sexual-dimorphic perception of HRQOL according to 
biological differences between the two sexes has not been given much attention in the scientific 
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literature. Yet, sex-related biological differences in several physiological processes can modulate 
gastro-intestinal symptoms of active IBD as described previously21. Some of these are in direct 
relation to IBD, such as the observation of worsening bowel symptoms during the premenstrual 
and menstrual phase of the menstrual cycle in patients with IBD and irritable bowel syndrome, 
respectively21. Furthermore, considerable research has been devoted to studies of sex-differences 
in the perception of pain in general, and consistent findings show females are more sensitive 
than males to nociceptive stimuli6. Although no such study has been performed specifically 
in an IBD patient population, in the context of these generally observed differences it seems 
plausible that the increased sensitivity of females to nociceptive stimuli, including visceral 
ones22, can be translated into a lower quality of life in female IBD patients compared with males. 
Finally, as discussed later, disease presentation, its natural course, and the responses to therapy 
differ between men and women with IBD, and these respective differences can contribute 
to the sex-specific perception of the impact the disease has on everyday life. Thus, women 
with IBD report consistently lower HRQOL than men. There are indications that this is owed to 
the gender-specific perception of disease complications, but biological differences between 
the two sexes are likely to play a role as well. A thorough analysis of the mechanism underlying 
this phenomenon is indispensable in order to develop gender/sex-specific interventions with 
the ultimate goal of improving the quality of life of IBD patients.
SEX
Because of the intestinal mucosal immune system’s aberrant response against autologous 
luminal flora, IBD belongs to the so-called immune-mediated or autoimmune diseases. The 
female predominance in autoimmune disorders has long been recognized23, but the mechanism 
of this dimorphism is still unknown. Most studies dealing with the sexual dimorphism of 
immune responses and autoimmune features focus on ‘classic’ immune-mediated inflammatory 
diseases, i.e. systemic lupus erythematosus, multiple sclerosis, and rheumatoid arthritis. So far, 
no studies have been performed on this subject in IBD, although this chronic immune-mediated 
inflammatory condition affecting the gastrointestinal tract features clear sexual dimorphism 
with regards to female predominance in adults24, disease phenotype with a higher prevalence 
of extra-intestinal manifestations in females25, and disease behaviour, with a more complicated 
disease course26, 27 and higher disease activity in females28. Additionally, although not yet studied 
in depth, there are indications that females are more prone to experience immunogenicity of 
anti-TNF monoclonal antibodies29, 30, which may underlie the role of sex in immune reactions 
with an important impact on disease management. 
Among the proposed mechanisms of the female-specific increased susceptibility to 
autoimmunity, two main pathways are implicated. Firstly, the influence of sex hormones on both 
innate and adaptive immune mechanisms have been studied31 and led to important insights 
into the modulation of the innate and adaptive immune responses through sex hormones. 
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However, this modulation cannot explain the whole spectrum of female autoimmune features, 
and probably only represents one part of the implicated pathologic mechanism. Secondly, our 
increasing understanding of the role of the X-chromosome in the sexual dimorphism of immune 
responses has turned the focus towards the mechanisms that would directly (i.e. not through 
the effect of sex hormones) involve X-chromosome anomalies in autoimmunity32. Interestingly, 
one of the susceptibility loci for IBD was located on the X-chromosome33, 34, although this has 
not been shown in the genome-wide scan35, possibly because the methodological specificities 
of gonosomal genetics were not taken into account36. Furthermore, the strongest risk factor 
for IBD is a positive family history, which is subject to female imprinting37, supporting the 
hypothesis of X-chromosome anomalies being involved in the pathogenesis of IBD. 
Thus, there are indications that sex plays an important role in the aetio-pathogenesis of 
IBD. The underlying mechanism by which sex contributes to the specific disease presentation, 
prognosis, and therapy success remains to be unravelled. However, the extent of the problem 
must first be determined through well-designed epidemiological and observational studies in 
order to generate a hypothesis on the mechanisms of sex-mediated IBD aetio-pathogenesis.
RePRODUctIOn
The importance of reproductive issues for chronically ill patients has long been underestimated 
and left out of both research and clinical practice agendas. That this essential need has been 
ignored in a life-long disease has led to the current situation in which most of the drugs used 
by chronically ill patients have insufficient data regarding the safety of their use during peri-
conception and/or during pregnancy38, 39. Owing to the obvious ethical considerations, no drug 
enters the market approved for use by mothers- and fathers-to-be. The results of animal studies 
on teratogenicity generally have limited predictive value for the human situation40. Human 
data on the safety of a particular drug in this setting are gathered with much difficulty through 
different registries, and are per definition obtained in a retrospective study design prone to 
selection and recall bias. Additionally, most of these studies are underpowered and suffer from 
the lack of a proper control population. The disease itself can have a great impact on all aspects 
of reproduction, resulting in a situation where neither healthy controls nor patients with the 
same disease but different phenotypes, which do not necessitate the use of a particular drug, 
can serve as a proper control. Thus, the patient with a reproductive wish who depends on the 
medication and the physician giving the pre-conceptional counselling are both left with a very 
limited body of evidence to enable them to make an informed decision.
IBD represents a typical example of this complicated situation. The peak incidence of the 
first presentation of IBD is in the third decade of life, and a quarter of the patients conceive for 
the first time after their diagnosis41. Therefore, family planning for these young, chronically ill 
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patients often interferes with different therapeutic interventions, be it drugs or surgery, that are 
necessary to control the disease. Reproductive issues are of key concern to IBD patients42. In this 
respect, it is important to note that IBD patients remain voluntarily childless more frequently 
than non-IBD controls42-44. IBD patients refrain from having children because of concerns about 
the adverse reproductive outcome, fear of side-effects of the medication on the child, and 
medical advice given by physicians42.  This is not surprising considering the lack of prospective 
and controlled cohort studies which determines that the actual management of IBD patients 
with regard to fertility and pregnancy issues is based on expert opinion and a few case-control 
trials45.
Reproduction in IBD patients is influenced by two overlapping factors; the disease itself, 
and the therapeutic interventions. The impact of the disease has been studied previously46-52. 
The results of these studies are conflicting, ranging from an important impact of the disease 
on male and female fertility to (sub)normal fertility findings in this patient population. These 
discrepancies were thought to be because of the historical differences between the studied 
cohorts, with recent studies reflecting the use of novel therapeutics that would result in better 
disease control and unimpaired fertility. Moreover, keeping the disease in remission has been 
shown to be essential, not only for the success of conception, but also to ensure a favourable 
pregnancy outcome45. Thus, IBD does not preclude male and female IBD patients having 
children, provided the disease is in remission, which again underscores the importance of the 
question of the safety of the medications necessary to control the disease in this setting.
In the past years, new therapeutic agents, i.e. monoclonal antibodies directed against human 
tumour-necrosis alpha (anti-TNF), were used to treat IBD. To date, two distinct anti-TNF agents 
have shown efficacy in the treatment of IBD; infliximab (IFX)53, 54 and adalimumab (ADA)55, 56. 
Because of the human specificities of these biologicals, it is not possible to do animal studies 
to evaluate their peri-conceptional safety or use during pregnancy. Human data on the use 
of IFX and ADA during pregnancy are limited to short-term observations57-60 where IFX and 
ADA use during pregnancy seems to be safe for the child. However, concerns about placental 
transfer and an ensuing neonatal exposure to these agents post partum have triggered an 
active discussion about the proper management of IBD patients using anti-TNF agents during 
pregnancy. However, constructive discussion cannot take place in the absence of good quality 
clinical data and without careful interpretation of the immune processes of both the mother 
and child. 
With regards to the safety of anti-TNF agents for fathers-to-be, data are limited to case series 
that analysed the effects of these agents on semen quality61, 62. The study by Mahadevan et al. 
in 10 patients using IFX showed a decreased sperm motility; however, in a study by Villiger in 
patients with ankylosing spondylarthritis using IFX, ADA, or etanercept compared with healthy 
controls, these defects in sperm quality were shown to also occur frequently in the general 
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population. Thus, data on the effect of anti-TNF agents on semen quality are inconclusive. 
Furthermore, the translation of data on sperm motility and concentration into its quality with 
regards to DNA damage is only an approximation, and there is a great need for follow-up of 
children conceived by fathers who used anti-TNF agents.  Favourable pregnancy outcomes with 
indirect exposure to IFX are reported58, 60, but no data are available on the use of adalimumab 
by future fathers. 
In conclusion, choosing therapeutic strategies for IBD patients with reproductive wishes is 
difficult and guided by a compromise between disease activity and potential side-effects of 
the therapy on the embryo/foetus/newborn. Therefore, good quality data with prospective 
assessment of the outcomes of pregnancies and long-term patient follow-up together with an 
understanding of pharmacokinetics of particular drugs in this setting are of extreme importance 
to develop responsible therapeutic protocols for use during peri-conception and pregnancy.
SUmmARY, AIm, AnD OUtLIne OF tHIS tHeSIS
In conclusion, there is ample reason to assume that gender- and sex-specific issues, especially 
those related to procreation, are of great importance in both basic research and clinical care in 
IBD. There is sexual dimorphism in the perception of the disease, its incidence, presentation, 
phenotype, natural course, and in treatment success. These issues should be taken into account 
to optimise patient care. Importantly, however, hard data are lacking, hampering meaningful 
discussions on this subject. The current work was undertaken to fill this void. 
In this thesis, the aim was to provide the grounds for a personalized approach to female and 
male IBD patients. More specifically, determining whether gender is really an important issue 
in IBD is explored by comparing the perception of quality of life in female patients versus male 
patients. The results show that female patients are significantly less capable of meeting life 
expectations compared with male patients, establishing that gender is an issue in IBD (Chapter 2). 
These results described in part I of this thesis give ground for further mechanistic studies of the 
underlying sex-specific basis of gender-determined perceptions of IBD. 
The sex-specific dimorphism of the disease aetio-pathogenesis and immune responses is 
delineated in part II of this thesis. In this part, we will establish that in familial Crohn’s disease 
the pathology manifests itself predominantly in females and involves epigenetic rather 
than classical genetic factors (Chapter 3). Subsequently, we will show that once the disease 
manifests itself, the success of immune suppressive pharmacological intervention is sexually 
dimorphic; women are at higher risk of developing allergic complications to certain types of 
medication (Chapter 4). The epigenetic factors leading to a female predominance in the familial 
presentation of Crohn’s disease may also result in more severe phenotypes, contributing to the 
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gender-specific differences in the perception of quality of life of IBD patients. In addition, more 
medication side effects will have a similar effect. Thus in toto, part I and part II of this thesis 
establish that gender is an issue in IBD and provides at least some insight into the sex-specific 
factors contributing to this effect. 
Whenever gender is discussed, the issue of reproduction cannot be ignored. This is even 
more true in IBD, which typically involves young adults who might be expected to want to 
procreate. Thus, in part III of this thesis, this subject is explored and evidence is provided that 
reproductive wishes are indeed an issue in IBD patients and that this is an important factor 
guiding treatment strategies (Chapter 5). Subsequently, we will further investigate how use of 
immune suppressive medication by the mother influences the health of the child, both in utero 
(Chapter 7) and through lactation (Chapter 6). The effect of discontinuing biological therapies 
during pregnancy is investigated in Chapter 9. Finally, the effect on conception is investigated 
from the male perspective (Chapter 8); however, no significant effects were found, emphasizing 
the female-specific nature of the gender-related problems in IBD. Chapter 10 contains a 
comprehensive discussion of all issues related to anti-TNF use during pregnancy.
Summarizing, this thesis shows that a gender problem exists in IBD, that rational sex-
dependent mechanistic explanations may be present, and describes the dilemma associated 
with pregnancy, especially for the mother, where the safety of continuing anti-TNF therapy is 
not yet assured. From the current investigation, it can be concluded that the time has come for 
a gender-specific approach in investigations of IBD and its clinical management.
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Introduction
Clinical practice shows that gender-related issues in inflammatory bowel disease (IBD) are of 
great importance. Previous reports showed that female gender is an independent predictor of 
decreased quality of life. However, no data are available on the gender-specific perception of 
the respective factors influencing the disease-related quality of life. 
Aims & methods
The aim of the study was to assess gender-related differences in the perception of respective 
factors influencing the quality of life in IBD patients. Between December 2006 and January 
2007, a patient empowerment study has been performed as a patients-initiated study in 
cooperation with Dutch Patients’ Crohn’s and Colitis association (CCUVN). All patients willing to 
participate completed an online questionnaire consisting of multiple-choice questions on the 
CCUVN website. Differences between men and women in the perception of particular quality of 
life influencing factors were analysed statistically by chi-square test. 
Results
In total 1067 (Crohn’s disease/ulcerative colitis, 617/450; 703 females/364 males, 66%/34%) 
replied. Significantly more females (F) than males (M) found that the disease limited them in 
everyday activities (53% F vs. 45% M, p=0.014). Only 9% of participating female patients vs. 19% 
of males almost never experienced disease-related limitations. 
Significantly more females than males encountered serious limitations in professional life 
such as work (42% F vs. 33% M, p=0.015) and study (36% F vs. 19% M, p<0.001). Furthermore, 
the disease was limiting more females than males in family life (31% F vs. 21% M, p=0.002), 
social life (35% F vs. 23% M, p<0.001) and sport (44% F vs. 34% M, p=0.004). No differences in the 
impact of disease on these activities were observed with regards to the type of the disease. 
Finally, as a result of the disease, significantly less female then male patients (44% and 55%, 
respectively; p=0.002) found that they were able to meet their daily expectations with regard 
to work or study, household, family and social activities. 
conclusion
Female inflammatory bowel disease patients experience more frequently the negative 
impact of the disease on the quality of life. Furthermore, there are important gender-related 
differences in the perception of particular factors influencing the quality of life. 
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IntRODUctIOn
Inflammatory bowel diseases (IBD) represent a chronic disorder affecting mainly young 
people between 20 and 40 years, with a substantial impact on the health-related quality of life 
(HRQOL)1-2. In the last years, an important achievement has been made in terms of implementing 
new therapeutic strategies in daily management of IBD patients. Nevertheless, the disease 
remains incurable and the course of the disease is for most patients characterized by remittent 
character unpredictably limiting their everyday life. Despite of the new treatment options, the 
HRQOL of IBD patients remains significantly decreased3. It is known that in the process of dealing 
with this chronic character and relapsing course of the disease, physical as well as psychological 
factors play an important role4-6 and the psychological impact of the chronic nature of the 
disease together with physical complaints lowers the HRQOL in IBD patients5,7. Considering 
the situation of limited effect of current therapeutic options on sustainable improvement of 
physical factors influencing HRQOL, understanding of psychological factors involved in HRQOL 
determination may help to improve the care for these chronically ill patients.
In general, the psychological impact of a chronic disease depends on coping with 
psychological distress due to life events and daily hassles5,7-12. Furthermore, the HRQOL depends 
on individual factors like anxiety and depression, acceptance of the disease, lack of energy, 
hopelessness, lack of self-efficacy, fears, body image and sexuality4,13-14.    
In IBD, factors that have been described to affect the HRQOL are gender, need for 
hospitalization, symptomatic activity, recurrence/year index and education level15. Especially 
female gender showed a significantly decreased HRQOL compared with male patients2,15-17. 
Although female gender is an independent predictor of decreased HRQOL no data are 
available on the gender-specific character of the HRQOL perception. Existence of gender-related 
differences in the perception of specific domains determining HRQOL (e.g. body image, sexuality, 
fertility) is a presumable hypothesis and may have great impact on further management of 
IBD patients. In the present study, we analyzed gender-related differences in the perception 
of the HRQOL areas using a patient empowerment study design. We found that, as a result of 
the disease, females feel not to be able to meet their expectations with regards to study/work, 
household, partnership and parenting significantly more frequently than male IBD patients.
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PAtIentS AnD metHODS
Between December 2006 and January 2007, a patient empowerment study has been 
performed as a patients-initiated study governed by Dutch Patients‘ Crohn‘s and Colitis 
association (CCUVN). The questionnaire was elaborated by a committee of patients. The part 
concerning quality of life consisted of two sets of questions dealing qualitatively (yes/no 
questions) and quantitatively (multiple choice questions with four categories) with the same 
quality of life areas. The quality of life areas/items were work and study, family, parenthood 
and hobbies/social activities. The quantitative questions included four degrees of experienced 
limitations – no limitations, hardly any limitations, serious limitations and extreme limitations. In 
order to analyse the gender-related differences in the perceptions of the limitations in different 
areas of life, the first two and the latter two degrees were pooled together.
The other parts of questionnaire concerned the individually reported compliance of patients 
(published previously by Baars et al Aliment Pharmacol Ther 2009) and the relationship with 
doctors.
The questionnaire was made public online on the CCUVN website and all patients willing to 
participate completed the survey online. The differences in reported quality of life restrictions 
between female and male patients were analysed by a chi-square test. This specific subanalysis 
has been performed with the agreement of the CCUVN.
ReSULtS
In total 1067 (Crohn‘s disease/ulcerative colitis, 617/450; 703 females/364 males, 66%/34%) 
replied. The baseline characteristics of the patient population are shown in Table 1. 
First, the overall gender-related differences in the quality of life perception were analysed. 
Significantly more females (F) than males (M) found that the disease limited them in everyday 
activities in general (53% F vs. 45% M, p=0.014). Only 9% of participating female patients vs. 
19% of males almost never experienced disease-related limitations. 
Second, gender-related differences in the specific areas of the quality of life were assessed 
(Table 2). The question ‘If you think about everything you would like to do in your life, are 
there any things that you would like to do but the disease is limiting your ability to do it?’ was 
answered in a qualitative way per each item proposed in the questionnaire. 
In general, significantly less female then male patients (44% and 55%, respectively; p=0.002) 
found that they were able to meet their expectations in everyday life as a result of the disease. 
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The specific everyday life`s activities being influenced by the disease in a gender-specific 
manner were as follows (Table 2): work, parenthood/having children, study, energy for family/
partner and household. 
Third, a quantitative analysis per each quality of life defining category (Figure 1-3) was 
performed. The categories were as follows: work and study, family, parenthood, hobbies/social 
activities. In addition, a general category of physical restriction/discomfort was analysed. In this 
subanalysis, no gender-related differences with regards to the experienced physical restriction 
and discomfort due to the disease were found. In the everyday life`s activities, significantly 
more females compared to males encountered serious limitations in professional life such as 
work and study (Figure 1). In personal life, the disease was limiting more females than males in 
family life and activities with partner; no differences were found in the limitations in activities 
with children. In the category of hobbies, females reported more limitations in doing sport 
(44% F vs. 34% M, p=0.004), going out (37% F vs. 25% M, p=0.0001) and going for holidays (39% 
F vs. 30% M, p=0.004) (Figure 3).
table 1. Baseline patients` characteristics
Responders 1067
Age (years; mean ± Sem) 43 ± 14
crohn`s Disease/Ulcerative colitis 617 / 450
males/Females 364 / 703
Disease duration
 0-2  years 179 (17%)
 3-8  years 313 (29%)
 9-15 years 277 (26%)
 more than 15 years 298 (28%) 
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table 2. Percentages of male and female patients not able to satisfy their life expectations 
overall and with regard to specific quality of life areas. The question was formulated in the 
questionnaire as follows: ‘If you think about everything you would like to do in your life, are 
there any things that you would like to do but the disease is limiting your ability to do it?’ 
  % of female patients % of male patients
“no limitations“ 44* 55*
travelling 26 24
„Outdoor“ activities 14 12
Work 17* 10*
Shopping 2 1
Parenthood 6* 0*
Social life 4 2
Study 6* 1*
Going out 8 5
Sport  0 1
energy for family/partner 4* 1*
Partnership 1 1
Sex 1 1
energy to continue 6 3
emigration 1 1
Hobby`s 3 2
Household 1* 0*
Doing nice thinks 1 1
Drink and eat 3 2
Spontaneous activities 1 0
not be dependent on the toilets 1 1
Read 0 0
Others 4 4
*p<0.05  
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Figure 1. Gender-stratified differences in the experienced limitations in professional life. 
Significantly more females compared to males encountered serious limitations in professional 
life such as work (42% F vs. 33% M, p=0.015; Fig 1A) and study (36% F vs. 19% M, p<0.001; 
Fig 1B). Grey bar –no/hardly limited, black bar – very/extremely limited
Figure 2. Gender-stratified differences in the experienced limitations in personal life. 
Significantly more females than males were limited by the disease in family life (31% F vs. 21% M, 
p=0.002; Fig 2A) and activities with partner (30% F vs. 21% M, p=0.007; Fig 2B). Grey bar – 
no/hardly limited, black bar – very/extremely limited
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Figure 3. Gender-stratified differences in the experienced limitations in hobbies. As a result of the 
disease, more females than males experienced limitations in sport (44% F vs. 34% M, p=0.004; Fig 3A), going 
out (37% F vs. 25% M, p=0.0001; Fig 3B) and going on holidays (39% F vs. 30% M, p=0.004; Fig 3C). Grey bar 
–no/hardly limited, black bar – very/extremely limited
DIScUSSIOn
In this large patient-empowerment study, we found several gender-related differences in the 
perception of the respective domains that determine health-related quality in IBD patients. 
More women with IBD experience negative impact of the disease on their quality of life 
compared with men. Female-specific life domains in which they perceived more limitations 
were professional life, private life and hobbies. We found no differences between male and 
female patients with regard to the perception of physical restrictions.
In general, women report lower HRQOL regardless of the questionnaire used or underlying 
condition which is also seen in IBD patients18,19. Our observations are thus in line with this 
previously reported phenomenon in various areas of clinical medicine. The decreased HRQOL in 
women may result from gender-specific psychology in which the burden of the disease would 
be perceived more intensely by women. On the other hand, biological differences underlying 
a more complicated disease course in female IBD patients may contribute to the low HRQOL 
in women18, 20. Considering the higher rates of disease-related symptoms in women than in 
men, as well as worse HRQOL perception in other diseases, our findings might be a logical 
consequence of both, psychological differences in the perception of disease burden as well as 
sex-specific disease biology21-22.
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Despite the more complicated disease course of female patients, females did not experience 
more physical restrictions in our study but they did report more limitations in doing sports, 
going out and going on holidays. This can be explained by different level of health utility 
between males and females but can also originate from gender-specific social expectations.
Our observation of gender-related differences in the perception of various domains 
determining the health-related quality of life has important consequences for understanding of 
the measurements of quality of life in IBD patients. To date, the measurement of the respective 
quality of life domains is lacking. The classical health-related quality of life questionnaires 
which deal preferentially with perception of physical restrictions do not measure the domains 
investigated in our study. Once validated in a prospective manner, these observations would 
give ground for the development of a new gender-specific questionnaire.
Since the study was internet-based and the participants were CCUVN members, the possibility 
of selection bias cannot be excluded. Neither was it possible to correct the results for the 
disease activity. However, the large size of the study population allows us to assume that the 
homogeneity of active or severe disease distribution as well as psychological factors between 
genders has been conserved. 
This patient-empowerment study shows patients` perspectives without any direct influence 
by the researcher. New insight gained in this study on the gender-specific domains influencing 
HRQOL can help to generate efficacious tools for the fine-tuning of the treatment and 
monitoring of the IBD patients. More specifically, female patients might benefit more from the 
active attention paid by their caregivers for their daily limitations, including specific copying 
trainings. More research is needed in order to develop and validate gender-specific tools for the 
assessment of the health-related quality of life.
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Background & Aim
Although the genetic risk factors for familial and sporadic inflammatory bowel disease (IBD) 
seem identical, the relative risk for contracting IBD in the familial setting is larger as that seen 
in the population at large, suggesting an important role of epi- and/or paragenetic factors in 
familial IBD. Epidemiological data indicate a female predominance in IBD, but how this relates 
to familial IBD has not been assessed. 
methods
Familial IBD patients (N=608) were compared with 415 sporadic IBD patients with regards to 
the patterns of sex and disease type distribution. The imprinting pattern in 87 families in which 
both a parent and a child had IBD was tested using Galton binominal statistics.
Results
The percentage of females in familial IBD population was significantly higher (61%; female/
male ratio 1.5) compared with sporadic IBD (54%; female/male ratio 1.2; p=0.011). The analysis 
of offspring sex distribution pattern revealed significantly higher female to female transmission 
compared with female to male transmission rate (36 vs. 18, respectively; p=0.02). A significantly 
higher number of mother to child transmissions (55 vs. 32 of father to child transmissions) was 
observed (p=0.018). The female imprinting was specifically related to Crohn`s disease (31 vs. 14 
mother vs. father to child transmissions, respectively; p=0.016). 
conclusion
We propose that a female sex-specific epigenetic inheritance pattern for Crohn’s disease is a major 
contributing factor in the family-specific risk in Crohn`s disease. Sex-specific manifestation of familial 
Crohn’s disease can partly explain the epidemiologically observed increased relative risk for females 
for contracting IBD.
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IntRODUctIOn
Among the major achievements in the field of genetically complex diseases has been the 
elucidation of the genetic risk factors contributing to the propensity for Crohn‘s disease and 
ulcerative colitis, recurrent gastrointestinal inflammatory disorders, with a still poorly understood 
etiology, that together constitute inflammatory bowel disease (IBD). The familial clustering of 
disease is highly suggestive of genetic factors playing role in the disease etiology and indeed 
especially in Crohn‘s disease (CD) but also in ulcerative colitis (UC) a plethora of risk genes has 
been identified from large genome-wide association that seem to underlie the genetic basis of 
IBD. Nevertheless, although familial clustering of disease was an important reason to embark 
on GWAS of IBD to identify its genetic determinants, the frequency and nature of the risk alleles 
subsequently discovered is more or less similar in both familial and sporadic IBD. Thus the familial 
clustering of IBD seems only marginally dependent on genomic determinants, and by inference 
epigenetic and/or paragenetic factors must be important to explain the orders of magnitude 
in increased relative risk for contracting the disease in familial IBD versus sporadic IBD. The 
mechanistic basis of these factors remains obscure at best and identifying and understanding 
these, remains one of large outstanding questions in IBD research. 
In the past years, it has become increasingly clear that gender is an important factor in both 
the clinical presentation of IBD and its subsequence response to therapy. There is a male pre-
dominance in pediatric population1 whilst an overall female predominance seen in IBD popu-
lation start with the adolescent and adult onset of the disease2. Other sex-related biological 
differences are reflected in the disease phenotype, with female predominance in CD and more 
male patients in UC population and a sex-specific distribution of the different types of extra-in-
testinal manifestations3. The strength of the female predominance differs significantly depend-
ing on the cohort and can vary from equal sex distribution to female/male ratio of 2.5:14-12. Fur-
thermore, some reports suggest a differential disease course, with a more complicated disease 
course in female patients13,14. Importantly, how these differences are related to familial disease 
versus sporadic disease dichotomy in IBD has not been investigated, but if detected could re-
veal important clues as to pathogenesis of familial IBD. 
Some of the differences observed between male and female IBD fits well with a classical ge-
netical interpretation, as recent reports have provided evidence for sex-specific risk variants 
for IBD. The R30Q DLG5 variant has been shown to confer differential risk for CD dependent 
on the sex in several independent populations15-17. Recently, a variant of IL-23 receptor, L310P, 
has been shown to protect from with ulcerative colitis in female but not in male population18. 
Furthermore, the two functional SNPs in the promotor region of IL-10 were found to be associ-
ated with ulcerative colitis only in female patients19. Thus some genetic variants seem only to 
contribute to IBD pathogenesis in the context of one particular gender. Although the effects 
detected are certainly too small to explain the female preponderance in epidemiology of IBD, 
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the detection of such sex-specific variants in especially IBD families indicates that a sex-specific 
manifestation of the disease may be important in familial IBD and call for further research to 
prove this notion. 
The indications on one hand that gender may play a role as a modifier of the genetic predis-
position for IBD, whereas the need for further data as to the nature of familial IBD prompted us 
to study the sex-specific inheritance pattern in the familial IBD patients‘ population. First, we 
assessed the sex distribution pattern in IBD patients‘ population with familial IBD compared 
with the baseline IBD population. Subsequently, the sex-related transmission pattern in the 
families with affected parent and child was studied. We detected a female sex-specific epige-
netic inheritance pattern for CD that is a major contributing factor in the family-specific risk in 
IBD. Furthermore, this sex-specific manifestation of familial Crohn‘s disease can largely explain 
the epidemiologically observed increased relative risk for females of contracting IBD observed 
in the population at large. 
PAtIentS AnD metHODS
Patients
IBD patients with family history of IBD were identified in the IBD research databases in two 
academic medical centra (AMC, Amsterdam; Erasmus MC, Rotterdam, The Netherlands). These 
research databases comprised all IBD patients under the follow-up at the outpatient clinic. Fam-
ily history of IBD was considered as positive if first and/or second degree relatives of patients 
were affected by IBD. Family relationship, sex and the type of the disease (CD, UC) were retrieved 
from the databases and the sex distribution in the population of familial IBD was compared to 
the control IBD population. For the analysis of imprinting, families were selected where both 
parent and child were affected. Patients and their relatives participated in previously published 
studies20-22. Local medical ethical committee approval was obtained for these studies. Since the 
present study consisted in the analysis of already collected data, no particular medical ethical 
approval was solicited. The control population comprised all IBD patients without family history 
of IBD followed at the IBD outpatient clinic in one medical center (Erasmus MC) in 2008. The 
sporadic character of the disease was retrieved from the patients‘ records of medical history 
and in case of doubt the patients were asked during their outpatient visit to confirm that they 
had no relatives with the family history of IBD.
Statistical analysis
To compare the respective proportions of males and females in familial population with 
baseline population a chi-square test was used. Galton statistics using the two-tailed binomial 
distribution test with test proportion of 0.5 was used to analyze the imprinting pattern in the 
subset of the families in which both, parent and child had IBD.
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ReSULtS
Female preponderance in the risk for contracting IBD is strong in familial IBD and slight 
in the sporadic IBD manifestation
The control population comprised 415 IBD patients; 278 CD, 128 UC and 9 patients with un-
classified IBD. There was a slight female predominance in the baseline population with female/
male ratio 1.2. The control population was compared with 608 IBD patients (363 patients with 
CD, 233 patients with UC and 12 patients with unclassified IBD) from 289 families with at least 
two family members affected with IBD. A higher percentage of CD patients was found in the 
control population compared to familial IBD population (respective 67% and 60%), this differ-
ence did not reach the statistical significance (p=0.05). The percentage of females in familial 
population was substantially and significantly higher compared with the control population, 
61% (female/male ratio 1.5) vs. 54% (female/male ratio 1.2), p=0.028 (Table 1).
The definition of sporadic IBD is strongly dependent on the reliability of the family history. 
Once the possibility of documentation error is excluded by contacting the patients directly, 
still other factors can lead to wrong allocation of a patient as having the sporadic disease 
and include him/her erroneously in the control group. The most common of these factors are 
young age and/or short duration of the disease. Both these factors are placing the patient in 
the period of life where they or do not have children yet or not enough time has elapsed for 
other relatives to develop the disease. The inheritance studies using a control population with 
sporadic IBD disease are likely to suffer from this bias. We therefore performed a subanalysis 
of the differences of sex distribution between the familial IBD population and an arbitrary 
chosen subpopulation of the control population in which only patients older than 50 years 
were included. This subpopulation of 140 patients showed an underrepresentation of females, 
with female/male ratio of 0.9 which differed significantly from the sex distribution in familial 
IBD population with female/male ratio of 1.5 (p=0.006). To mean duration of the disease in 
this subpopulation of patients older than 50 years was significantly longer compared with the 
patients with sporadic disease younger than 50 years (19±SEM 1 vs. 11±0.5 years, p<0.001), ex-
cluding thus the possibility that these patients represent a specific subgroup with a late onset-
disease which would make them not representative for the whole population. Thus specifically 
familial IBD is strongly skewed towards a female presentation of the disease and sporadic IBD 
much less so. 
the female-specific manifestation of familial IBD is restricted to cD 
Subsequently the sex-specific inheritance pattern was analyzed. The families where both, parent 
and child were affected were identified. In total 92 families with parent–child pairs were found, of 
which in 5 families both parents were affected and these 5 families were excluded from further 
analysis. From 87 families analyzed, in 55 cases the mother was affected vs. 32 families with affected 
father (p=0.018), (Table 2, Fig. 1). In the subgroup analysis with stratification according to the dis-
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ease type (Table 2), this maternal imprinting was only present in the families were parent was af-
fected with CD, with 31 families with affected mother vs. 14 families with affected father (p=0.016). 
Female specific transmission in familial cD 
An important question is whether the female sex specific manifestation of CD is only parage-
netic (e.g. familial CD only occurs in presence female hormones), or also epigenetic (e.g. female 
specific transmission of risk via imprinted alleles). In the former case (paragenetic factors), the 
female bias in risk would be maintained over the generations even if the father transmits the 
disease. In case of the latter (e.g. an epigenetic factor imprinted through maternally-transmit-
ted alleles), transmission of the disease via a father would not be associated with increased risk. 
For this analysis of the sex distribution among the affected offspring, two families with multiple 
affected offspring were excluded; the remaining 85 families were analyzed further. In 54 fami-
lies with an affected mother, 36 of the affected offspring were females and 18 males (p=0.02), 
(Fig. 1). There was no sex-specific pattern of disease transmission in the subgroup of the families 
where the disease was transmitted from the father. In the subanalysis stratified according the 
disease type, this mother-to-daughter transmission of the disease was found only in the fami-
lies where parent was affected with Crohn‘s disease (Table 3). Thus a female specific imprinting 
in the inheritance of CD explains to large extent the female predominance in IBD and is a major 
contributor to the strongly increased risk in familial IBD when compared to sporadic IBD.
 
table 1. Sex distribution in familial and baseline IBD patients’ population
 Familial IBD population  Baseline IBD population
nr of patients 608 415
crohn`s disease 363 (59.7%) 278 (59.6%)
Ulcerative colitis 233 (38.3%) 128 (37.4%)
Unclassified colitis 12 (2%) 9 (2%) 
Female/male (ratio) 369/239 (1.5) 223/192 (1.2)*
*p=0.028, chi square test
table 2. Sex-specific inheritance
 nr. of families mother to child Father to child Binomial test p value*
total 87** 55 32 0.018
cD parent 45 31 14 0.016
Uc parent 39 21 18 0.749
*binomial, two-tailed test p-value, test proportion 0.5
**three parents with unclassified colitis
 46 Chapter 3
Paternal 
transmission
(N=32)
Maternal 
transmission
(N=55)
37% 63%
A B
100
80
60
%
 o
f a
ll 
o
sp
ri
ng
40
20
0
Paternal transmission
(n=31)
Maternal transmission
(n=54)
p=0.02* p=n.s.*
33%
67%
58%
42%
table 3. Sex distribution among affected offsprings
 mother to child transmission Father to child transmission
total nr of Families 54 31
  - Female offspring 36 13
  - male offspring 18 18
   (p=0.02)* (p=0.473)* 
cD parent 30 13
  - Female offspring 23 5
  - male offspring 7 8
   (p=0.005)* (p=0.581)* 
Uc parent 22 17
  - Female offspring 12 8
  - male offspring 10 9
 (p=0.832)* (p=1)* 
*binomial, two-tailed test p-value, test proportion 0.5
Figure 1. Sex-specific inheritance and the sex-distribution pattern among the offspring. 
In the families with parent and child affected, significantly higher transmission rate from the 
mother was observed (p=0.018*), (Figure 1A). Significantly higher percentage of affected fe-
male offspring was found in the families with maternal transmission whereas no sex-specific 
distribution pattern among the offsprings has been detected in the families with paternal 
transmission (Figure 1B; black bars – female offspring, grey bars – male offspring). *Galton bi-
nomial, two-tailed test, test proportion 0.5
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DIScUSSIOn
In this study, we found that the female predominance characteristic for adult IBD popula-
tion is a feature of familial IBD. In this familial IBD population with female predominance, we 
describe a specific pattern of inheritance in the families with parent and child affected with 
Crohn‘s disease with significantly higher disease transmission rate from mothers. With respect 
to the sex of the offspring, this transmission is characterized by prevailing female sex among 
affected children.
Our findings are in line with previously reported female predominance in familial IBD23-25 and 
the phenomenon of increased risk of CD in offspring of mothers with CD in a non-Jewish familial 
IBD population26. This sex-specific modification of genetic predisposition for IBD suggests the 
existence of genetic factors that are specifically translated into diseased phenotype in females. 
One of the possible genetic factors involved might be genomic imprinting, an epigenetic form 
of gene regulation in which only one member of the specific gene pair is expressed depending 
on whether it is inherited from the father or the mother. Genomic imprinting has been increas-
ingly studied in the last years and has been suggested as etiological factor for several disorders 
with sex-specific distribution27-29. It is tempting to speculate that this factor might play a role in 
the female imprinting observed in IBD familial population. 
The possible genetic factors are the transmission of genetic variants present in mitochondrial 
DNA and X-chromosome. Although, in case of disease transmission through variants in mito-
chondrial DNA an equal distribution of the disease among both sexes of the offspring would 
be expected, this factor cannot fully be excluded if also paragenetic factors contribute. To ad-
dress this possibility, multi-generation families would have to be analysed in order to detect 
the expected stop of the disease transmission through male intermediates. Thus, we cannot 
exclude the possibility of the transmission through genetic variants located in mitochondrial 
DNA and mitochondrial DNA analysis has not been studied yet in this context in IBD popula-
tions. Concerning the transmission through variant(s) located on X-chromosome, a susceptibil-
ity locus on X-chromosome has been found in a linkage analysis study with basic population 
of familial IBD30,31 but the genome-wide meta-analysis did not find susceptibility loci on this 
chromosome32. 
Although apparent absence of male transmission in familial CD fits ill with an important role 
for paragenetic factors in the risk of contracting familial IBD, there is still a slight bias towards 
female disease in our non-familial CD population. Although undetected familial cases will cer-
tainly contribute to this basis, in context of epidemiological data showing a male predominance 
in pediatric population with the onset of the disease prior to puberty2 one can speculate about 
the contributive role of female sex hormones as risk factor for females with inherited predispo-
sition to develop IBD. Both, endogenous female sex hormones which cyclic changes starting 
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around puberty, as well as exogenous female sex hormones through oral contraceptives (OCs) 
might play a role. Discrimination between these two factors based on epidemiological data is 
difficult as the onset of endogenous hormonal activity in Western society is often related to 
start of sexual life and with it associated use of the OCs. Interestingly, OCs have been proposed 
as a risk factor for the development of CD33,34, although this risk seems to be modest with results 
of the metaanalysis by Godet et al.35 showing the pooled relative risk after adjusting for smok-
ing of 1.44 (CI 1.12– 1.86). Nevertheless, the contribution of these effects towards the increased 
risk for females for contracting IBD in patient population in toto, seems minor in comparison to 
the risk conferred to female specific transmission in especially familial CD.
In conclusion, we observed female predominance as a feature characteristic for familial in-
flammatory bowel disease. In CD, the female predominance may be related to the imprinting of 
the disease predisposition with a specific female to female transmission pattern. This transmis-
sion pattern suggests existence of female-specific modifier of genetic predisposition for the 
disease. The epigenetic female transmission of CD is a major contributing factor to the familial 
presentation of disease and explains to a large extent the epidemiologically-detected female 
bias in the risk for contracting IBD.
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ABStRAct
Background
Limited data are available on the sex-specific adverse drug reactions (ADR) to 
immunosuppressive medication. In this study we analyzed sex differences in the incidence of 
ADR to the immunosuppressive medication in inflammatory bowel disease (IBD) patients.
methods
The electronic medical records of IBD patients were reviewed, the reported ADR to immune 
suppressive drugs used for IBD were noted and the sex differences in ADR were analyzed.
Results
In total, 843 IBD patients were included. No differences between males and females were 
observed with regard to specific ADR to thiopurines, methotrexate and cyclosporine but 
significantly more females (54 patients, 39% of all female users of anti-TNF) than males (23 
patients, 23% of all male users of anti-TNF) experienced ADR to one or more anti-TNF agents 
(p=0.011, OR 2.2, 95% CI 1.2-3.8). The most frequent ADR were allergic reactions. As a result of 
ADR, 36 patients (15% of all patients using anti-TNF) stopped the treatment, with significantly 
higher stopping rate among females (27 females, 19% vs. 9 males, 9%, p=0.024). 
conclusion
Treatment with anti-TNF antibodies is accompanied by sex dimorphic profile of adverse 
drug reactions with female patients being more at risk for allergic reactions and subsequent 
discontinuation of the treatment.  
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IntRODUctIOn
The existence of a sex dimorphic profile of adverse drug reactions (ADR) has been increasingly 
recognized in recent years. Several studies on various therapeutics pointed to differences 
between sexes in the incidence as well as character of ADR. In general, females seem to be 
more at risk for ADR to various medication, 70% of drug users with ADR in a large cohort of 
2367 patients being women1. In addition to this generally increased risk of ADR, female patients 
also differ from males in terms of types of ADR to a range of medication such as antiarrythmics, 
antipsychotics, anti-retroviral drugs, and analgesics2, 3. 
A limited number of small size studies performed in the field of auto-immune diseases 
and transplant medicine suggested existence of a sexual dimorphic profile of ADR to 
immunosuppressive medication, but this has not been studied in depth. Male sex has been 
reported as a risk factor for nodular regenerative hyperplasia in inflammatory bowel disease 
(IBD) patients treated with azathioprine4. In rheumatoid arthritis patients` population, males 
have been shown to be more at risk than females for methotrexate-associated interstitial 
pneumonia5 and to bacterial pneumonia complicating treatment with infliximab6. For females, 
a higher incidence of azathioprine-related alopecia has been reported in transplant recipients7. 
In a pediatric population of Crohn`s disease (CD) patients, female sex was one of the risk 
factors for infusion reactions to anti-tumor necrosis factor (anti-TNF) treatment8 and in an adult 
population of ankylosing spondylitis patients, females were more at risk of discontinuation of 
anti-TNF agents9.
The sexual dimorphism of the immune responses is a generally accepted concept that has been 
studied predominantly in the context of the female predominance in autoimmune disorders10 
with the most important factor determining this dimorphism being the immunomodulatory 
properties of sex hormones. Considering these differences between the two sexes in basic 
immune reactions, further modulation of immune response by the immunosuppressive 
medication might have sex-specific consequences, including the quantitative and qualitative 
differences in ADR to these agents.
The limitations resulting from ADR for further therapeutic strategy in patients with chronic 
inflammatory conditions such as inflammatory bowel diseases (IBD) are important. The ADR 
occurring in up to 20% of IBD patients using immune suppressive and anti-TNF agents11, 12 
represent an important factor leading to the modulation or discontinuation of effective 
treatment. The thorough understanding of the underlying mechanism of ADR to these drugs, 
including the sex-related differences would help optimizing the therapy in these patients.
Therefore, in the present study we aimed to specifically determine the difference between 
male and female IBD patients in the occurrence and type of ADR to commonly used 
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immunosuppressive agents, including ‘classical’ immunosuppression, i.e. thiopurines and 
methotrexate, as well as anti-TNF agents. In this large retrospective study, we found a sex 
dimorphic profile of ADR to anti-TNF agents with females being at increased risk for allergic 
reactions compared with males limiting thus the long-term use of anti-TNF in substantial 
proportion of female IBD patients. 
PAtIentS AnD metHODS
Patients
IBD patients attending the outpatient clinic of the Department of Gastroenterology and 
Hepatology of the Erasmus MC were identified through the electronic diagnosis registration 
system. The medical records were reviewed with emphasis on details of drug treatment. 
Reported ADR to immunosuppressive and anti-TNF agents used for IBD were noted. Patients 
for whom the required information on drug use and potential side effects was not available 
in the electronic medical record and patients with only one registered contact and no further 
follow-up at the outpatient clinic were excluded. 
Definition of ADR
All ADRs designated as such by the treating physician in the medical record were registered. 
The general definition of ADR used in clinical practice comprised the occurrence of the ADR in 
the temporal relationship with its disappearance upon discontinuation of the medication. In 
case of doubt about other concomitant factors contributing to the ADR a positive re-challenge 
was considered to be necessary for the event to be definitely categorized as ADR. 
The ADR to immunosuppressive agents were divided into the following categories according 
to the type of symptom/event: gastro-intestinal, arthralgia and/or myalgia, cutaneous, 
infectious, malignancy, myelosuppresion, hepatotoxicity, or pancreatitis. In case of anti-TNF 
agents, additional categories of allergic reactions, lupus-like syndrome, and injection-site 
reactions were used. 
Gastro-intestinal ADR comprised abdominal pain recognized by the patient as different from 
the IBD-related pain, diarrhea, nausea, and vomiting. Cutaneous ADR were defined as any kind 
of reported skin abnormality that occurred in temporal relationship with the treatment and 
resolved after cessation of the medication. Remittent or opportunistic infections occurring 
during the immunosuppressive treatment were noted as infectious ADR. For malignancies, any 
malignancy that was revealed during the use of the treatment was categorized as ADR. 
Myelosuppression was defined as leucopenia (leucocytes count<4.0x109/L), and/or anemia 
and/or thrombocytopenia (thrombocytes count<150x109/L). To categorize abnormal liver tests 
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as hepatotoxic ADR, the increase of liver tests above 2 times upper normal value and absence 
of other causes, i.e. viral or autoimmune were required. Drug-induced pancreatitis was defined 
as a new abdominal pain and hyperamylasemia occurring during the treatment.
Any of the following symptoms occurring during or within one day after infusion alone or 
in combination were considered as allergic reactions: skin reactions, dyspnoe, chest pain, low 
blood pressure, angiooedema, fever and/or chills. Dyspnoe, skin abnormalities and arthralgia/
myalgia occurring later than two days after infusion were categorized separately as potential 
delayed allergic reactions. Any motoric or sensoric loss, paresthesia and/or seizures were 
categorized as neurological ADRs. Lupus-like syndrome diagnosis was characterized as the 
combination of arthritis and/or flu-like symptoms or fever and presence of anti-nuclear and or 
anti-doublestrand DNA antibodies. Injection site reactions (applicable for adalimumab) were 
defined as pain or local skin reaction after injection. 
Non-specific ADR which could not be categorized according to these criteria were analyzed 
together and are further referred as others.
Statistical analysis
The sex-related differences in categorical variable were analyzed statistically using two-sided 
chi-square testing, for continuous variables a two-sided independent t-test was used. P-values 
<0.05 were considered significant. The analysis was performed using SPSS PASW 17 software.
ReSULtS
Demographic characteristics and the use of medication
In total, 843 patients were eligible for analysis, 386 males (46%), mean age 42 yrs (range 16-
87) with a mean duration of the disease of 14 years (range 0-54); 578 patients with Crohn`s 
disease, 244 with ulcerative colitis (UC) and 21 with unclassified colitis. There were no differences 
between male and female patients with regard to age and disease duration; significantly more 
males suffered from ulcerative colitis (141 pts, 58% of all ulcerative colitis patients).
Seventy percent (586 pts) of patients used any kind of immunosuppressive agents during 
the disease course, the majority of the patients (546 pts, 65%) used thiopurines, 176 pts (21%) 
methotrexate, 46 pts (5%) cyclosporine and one patient tacrolimus. No differences between male 
and female patients were observed with regard to the frequency of use of immunosuppressive 
agents in general or of particular agent.
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One third (240 pts, 28%) of patients were treated with anti-TNF, the majority of patients 
(227 pts, 27%) used infliximab, 96 (11%) adalimumab and five patients certolizumab. There 
were no sex-related differences in the use of anti-TNF agents (Table 1).
Adverse drug reactions to immune suppressive agents
In total 278 patients experienced ADR to immunosuppressive agents; of which 155 patients 
to thiopurines (28% of all thiopurine-treated patients), 44 to methotrexate (25%), 2 (4%) to 
cyclosporine, and 77 pts (32%) developed ADR to one or more anti-TNF agents. 
Overall, there were no significant differences in the frequencies of the ADR to immune 
suppressive agents between males and females. In total, 27% of males (71 pts) experienced 
ADR to any kind of immune suppressive agent compared to 34% of females (108 pts; p=0.087), 
(Figure 1A). 
Among thiopurines users, 26% of males (63 pts) and 31% of females (92 pts) suffered 
from ADR to thiopurines (p=0.183), (Figure 1B). The most frequent ADR to thiopurines were 
myelosuppression, hepatotoxicity (both in 33 pts, 6%) and gastro-intestinal ADR (23 pts, 4%), 
(Table 2). No differences between male and female patients were observed with regard to 
specific type of ADR to thiopurines. 
In the group of patients treated with methotrexate, 27% (20 pts) of males and 23% (24 pts) of 
females experienced ADR (p=0.597), (Figure 1B). The most frequent ADR to methotrexate were 
hepatotoxicity and gastro-intestinal ADR (both in 10 pts, 6%), (Table 2). 
Out of 46 pts treated with cyclosporine, two female patients experienced an ADR, one 
developed pseudo-membraneus colitis following treatment but she was also treated with 
systemic steroids. The second patient had a cutaneous reaction to cyclosporine.
Among 77 pts who developed ADR to one or more anti-TNF agents, significantly more females 
(54 pts, 39% of all anti-TNF treated women) than males (23 pts, 23% of all anti-TNF treated men) 
experienced ADR to an anti-TNF agent (p=0.011; OR 2.2, 95% CI 1.2-3.8), (Figure 2A). In the 
subanalysis of respective anti-TNF agents, significantly more females (51 pts, 38% of all IFX-treated 
women) than males (20 pts, 22% of all IFX-treated men) suffered from ADR to infliximab (p=0.009; 
OR 2.2, 95% CI 1.2-4.1). Relatively more females than males experienced ADR to adalimumab 
(16 females; 28% vs. 6 males; 15%), this difference was not significant though (p=0.216). 
The most frequent ADR to both infliximab and adalimumab were allergic reactions (15% 
of all infliximab users and 7% of all patients treated with adalimumab) and for both agents a 
significantly higher rate of allergic reactions in females compared with males was observed 
(Table 3). There were no other sex-specific ADR observed to anti-TNF agents.
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Of 77 patients experiencing ADR to an anti-TNF agent, 36 pts stopped the treatment (47%; 
overall discontinuation rate 15%), 27 pts (35%) switched to another anti-TNF agent, and 14 pts 
(18%) continued the treatment. As a result of ADR, 27 females (19% of all antiTNF-treated 
women) stopped the treatment compared with 9 males (9% of all antiTNF-treated men; 
p=0.024). Furthermore, significantly higher proportion of females (21 pts, 15% of all antiTNF-
treated women) switched to another antiTNF agents compared with males (6 pts, 6% of all 
antiTNF-treated men; p=0.026) significantly more frequently than males. 
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Figure 1. Relative percentages of male and female patients experiencing adverse drug 
reactions to immunosuppressive agents in general (Figure 1A); to respective immunosuppressive 
agents (Figure 1B). Black bars – adverse drug reactions present, gray bars – no adverse drug 
reactions. 
* two-sided chi-square test
Figure 2. Relative percentages of male and female patients experiencing adverse drug 
reactions to anti-TNF agents in general (Figure 2A) and stratified by respective anti-TNF agent 
(Figure 2B). Black bars – adverse drug reactions present, gray bars – no adverse drug reactions.
* two-sided chi-square test
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table 1. Demographic characteristics and the use of medication
n=843 males* Females* P value**
males/Females (% males) 386 (46%) 457 
Age (mean, range) 43yrs (16-87) 42yrs (18-87) p=0.138
Duration of the disease (mean, range) 14yrs (0-48) 14yrs (0-54) p=0.168
cD/Uc /Unclassified 233 (40%)/141 (58%)/12 (57%)  345/103/9 p<0.0001
Immunosuppressive agents 265 (45%) 321 p=0.652
 - thiopurines 247 (45%) 299 p=0.665
 - methotrexate 73 (42%) 103 p=0.203
 - cyclosporine 26 (57%) 20 p=0.170
 - tacrolimus 0 1
Anti-tnf 101 (42%) 139 p=0.193
 - infliximab 93 (41%) 134 p=0.102
 - adalimumab 39 (41%) 60 p=0.328
 - certolizumab 1 (20%) 4 p=0.401
* for each categorical variable number and percentage of males within the group is displayed
** p values for test of the sex-related differences; two-sided chi-square test for categorical variables and 
t-test for continuous variables
table 2. Categories of adverse drug reactions to immunosuppressive agents, in general and 
stratified by sex
  thiopurines thiopurines methotrexate methotrexate
  N, % of all  N of males N, % of all N of males
  patients treated (%)**  patients treated (%)**   
  with thiopurines  with methotrexate
myelosupression 33 (6%) 12 (36%) N/A N/A
Hepatotoxicity 33 (6%) 19 (58%) 10 (6%) 6 (60%)
Pancreatitis 10 (2%) 2 (20%) N/A N/A
Gastro-intestinal side-effects 23 (4%) 8 (35%) 10 (6%) 6 (60%)
Arthralgia and/or myalgia 11 (2%) 5 (45%) 2 (1%) 1 (50%)
cutaneous side-effects 10 (2%) 4 (40%) 3 (2%) 3 (100%)
Infectious 6 (1%) 3 (50%) 2 (1%) 1 (50%)
Others* 23 (4%) 7 (30%) 13 (7%) 2 (15%)
not specified 6 (1%) 3 (50%) 4 (2%) 1 (25%)
* headache, paresthesia, hair loss, fatigue, emotional instability, malaise; specific for methotrexate –
injection site reaction
** no significant difference observed between males and females for none of the ADRs as tested with 
two-sided chi-square test
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DIScUSSIOn
In this large retrospective study, we studied sex differences in the frequency and types of 
adverse drug reactions to immune suppressive medication in inflammatory bowel disease 
patients. In contrast to thiopurines and methotrexate with similar rates of ADR in both sexes, 
we observed a sex dimorphic profile of adverse drug reactions to anti-TNF agents with higher 
frequency of ADR among female IBD patients compared with male patients. With regard to 
particular types of ADRs, females experienced more often allergic reactions to the most 
frequently used anti-TNF agents, infliximab and adalimumab. In addition, these ADR have led to 
discontinuation of treatment more frequently in females than males, thus substantially limiting 
the long term use of anti-TNF agents by female patients.
The landmark randomized controlled trials on infliximab and adalimumab efficacy and safety 
did not reveal sex dimorphic profile of ADRs to anti-TNF agents13-17. However, the design of 
these studies with rather short follow-up might underestimate the overall incidence of ADR 
and immune-mediated ADR occurring at long term in particular. This would subsequently 
limit the sample size to study specific risk factors for the development of ADR. Another source 
of information on ADR, the safety registry with inclusion of patients being at the physicians` 
discretion are difficult to interpret with regard to sex differences in ADR incidence due to the 
possible selection bias and also a rather short follow-up18. Interestingly, in a large retrospective, 
real-life study on long-term safety of infliximab for the treatment of IBD, female sex was 
shown to be an independent risk factor for the development of hypersensitivity reactions 
and dermatological ADR to IFX12. In addition, one small size study with pediatric CD patients 
determined female sex as one of the risk factors for infusion reactions8. Thus, our results, in line 
with previous reports, suggest that female IBD patients are at specific risk for hypersensitivity 
reactions to monoclonal anti-TNF antibodies.
For each drug group with sex dimorphic ADR profile specific considerations for underlying 
mechanisms are applicable. The basic pharmacokinetic differences between the genders were 
at first considered to cause the predominance of ADR to some drugs in females, but over the past 
years, it became evident that sex hormones interacted with the particular drugs` metabolism 
and mechanisms of action3. The sex hormones greatly influence the immune responses which 
might also account for the sex differences in ADR to immune system modulating therapy. 
However, in the present study, only biological anti-TNF agents and no other immunosuppressive 
treatment showed a specific ADR sex dimorphic profile. In addition, the particular ADR 
presenting more frequently in females were hypersensitivity reactions, suggesting a female-
specific immunogenic potential related to biological therapy.  
ADR to monoclonal anti-TNF antibodies have been shown to be related to the development 
of antibodies against these agents. Anti-infliximab as well anti-adalimumab antibodies are 
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found in the sera of patients with loss of response and/or adverse drug reactions to IFX or 
ADA19-23, suggesting thus the humoral immune response as underlying mechanism of IFX- and 
ADA- related immunogenicity. Interestingly, some studies analyzing the sex differences in 
the humoral response to vaccinations showed higher antibody titers in females24, 25 and more 
local and systemic adverse reactions to influenza and rubella vaccines have been observed in 
women compared with men26, 27. The underlying mechanism of these sex differences in humoral 
immune response in general is not elucidated thus far, but taken all these observational data 
together, it is tempting to speculate that the use of monoclonal antibodies against TNF-alpha 
might result in higher anti-antiTNF antibodies formation rate in female patients which in turn 
would lead to the female-specific higher incidence of immune-mediated ADR. 
This immunogenic potential of anti-TNF agents resulting in ADR has important consequences 
for the management of IBD patients using these drugs. In this study, up to 50% of patients 
experiencing ADR discontinued the treatment, with the overall discontinuation rate of all 
patients using anti-TNF agents being 15%. There are thus considerable potential limitations of 
long term use of these otherwise effective drugs. Understanding the underlying mechanisms, 
one of which might be female-specific immunogenicity would subsequently help to identify 
patients at risk and modify the therapeutic strategy accordingly. 
To our knowledge, this is the first report studying the sex differences in ADR profile to 
immunosuppressive medication in a large cohort of patients with immune-mediated disease. 
The main limitation of our study is its retrospective design in which reporting bias of ADR is 
inevitable due to the lack of a standardized protocol that would ensure a meticulous screening of 
every treated patient in a prospective study design. This might particularly affect a study dealing 
with sex-related differences due to the psychosocial specificities of the two sexes in reporting 
ADRs. On the other hand, we analyzed sex-related ADRs profile to several immunosuppressive 
drugs in this large cohort. We found the sex dimorphism specifically applying only for anti-TNF 
agents and no other medication which would be the case if this reporting bias ensuing from 
retrospective design was substantially to modify the findings. 
In conclusion, female inflammatory bowel disease patients are at increased risk of 
hypersensitivity reactions to anti-TNF agents compared with males. These adverse drug 
reactions have important clinical consequences as they lead to the discontinuation of the 
treatment in half of the patients experiencing these reactions. Further research, with a specific 
consideration of sex dimorphism of the immunogenic potential of anti-TNF agents is warranted 
in order to improve the clinical management of patients at risk for adverse drug reactions.
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Part III - Reproduction
Chapter 5
Reproductive Wish Represents an Important Factor Influencing 
Therapeutic Strategy in Inflammatory Bowel Diseases
Zuzana Zelinkova, Peter BF Mensink, Jan Dees, Ernst J Kuipers, C Janneke van der 
Woude
Scand J Gastroenterol 2010;45:46-50
ABStRAct
Background
Inflammatory bowel diseases (IBD) affect patients in reproductive age but little is known abo-
ut the peri-conceptional use of medication for IBD.
Aim
To assess the type of medication used by IBD patients with reproductive wish and changes of 
the medication in the peri-conceptional period.
methods
IBD patients with active conception plans and pregnant patients were prospectively recru-
ited from the outpatient clinic of one academic medical center. IBD-related medication and 
changes of this medication for reasons of the conception wish or pregnancy were analyzed.
Results
In total 61 patients (51 females; 40 Crohn`s disease, 21 ulcerative colitis) were included. Thir-
teen (21%) patients used no medication, 44 (72%) used monotherapy and 4 (7%) patients used 
combination treatment. From patients on monotherapy, 11 (19%) patients used 5-aminosali-
cylates, 5 (9%) steroids, 11 (19%) thiopurines, 5 (9%) methotrexate and 11 (19%) used anti-TNF 
agents.
Thirty-seven patients (61%) consulted the physician prior to conception. One third of these 
patients required change of the medication due to the conception plans. 
conclusions
Two-thirds of patients with active reproductive wish use medication of uncertain peri-con-
ceptional safety profile. The reproductive wish leads to a change in medication in one third of 
these patients, influencing thus substantially the therapeutic strategy.
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IntRODUctIOn
Inflammatory bowel diseases (IBD) typically affect patients in their reproductive years. It has 
been shown that reproductive issues are of key concern to IBD patients1, especially women2. In 
this respect, it is important to note that IBD patients remain voluntary childless more frequently 
than non-IBD controls1,3,4. A recent study reported that IBD patients refrain from having children 
due to the concerns about the adverse reproductive outcome1. Fear of side-effects of the 
medication on the child and medical advice given by physicians, were the most important 
reasons for voluntary childlessness in this study.
Previous studies primarily focused on the determination of factors influencing the pregnan-
cy outcomes. Some IBD therapeutics have been shown to be related to adverse pregnancy 
outcomes, but these data are often retrospective and based on limited patient numbers or, as 
it is the case of biologicals, without long-term follow-up. The risk for complications during pre-
gnancy seems to be primarily related to disease activity and not to the specific medication5. The 
medical advice for IBD patients with active reproductive wish is therefore guided by a difficult 
compromise between the risks of active disease versus potential adverse-effects of the therapy 
on the pregnancy outcome. 
In the present study, we aimed to determine the actual clinical extent of this problem, i.e. 
how many patients with active reproductive plans need medication that is either contra-indica-
ted or has an unclear safety profile for use during the peri-conceptional period. For this purpo-
se, we prospectively assessed the medication used by the patients with active conception wish 
recruited from our outpatient clinic. In addition, we analyzed the medication changes resulting 
from the conception wish or pregnancy of IBD patients.
PAtIentS AnD metHODS
Between April 2007 and April 2009, all consecutive IBD patients with conception plans or 
pregnancy ongoing during the study period were recruited from the IBD outpatient clinic of 
the Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, the 
Netherlands. The medication used in the peri-conceptional period and changes in the medica-
tion for reasons of the conception plans and pregnancy were noted at each outpatient clinic 
consultation. In case of doubts the patient and/or the physician were contacted personally to 
specify the reason for the change of medication.
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ReSULtS
General
In total 61 IBD patients with active reproductive wish were included. The basic demographic 
characteristics, the type and localization of inflammatory bowel disease are shown in Table 1. 
Of all included patients, 23 (38%) patients consulted the physician after the conception, 38 
patients were included in the pre-conceptional period.
medication use
Only 13 (23%) patients used no medication during conception. Forty-four (72%) patients were 
using monotherapy and 4 patients were on combination therapy (all on infliximab with either 
azathioprine (2 patients), prednisone (1 patient), or mesalazine (1 patient)). Of the patients on 
monotherapy, 11 (19%) were using 5-aminosalicylates, 11 (19%) thiopurines, 3 (5%) systemic 
steroids, 2 (4%) budesonide, 11 (19%) anti-TNF agents (4 infliximab and 7 adalimumab), 5 (9%) 
methotrexate and one patient was treated by a trial medication (Figure 1). The respective use 
of medication by female and male patients is shown in Table 2 and 3, together with the desig-
nated FDA categories. 
changes in the medication
For reasons of the pregnancy or active reproductive wish, 15 patients (25%) changed their 
medication. Eleven patients, 30% of all patients consulting the physician prior the conception, 
changed their medication because advised so by their gastroenterologists. The patients were 
advised to postpone (2 patients) or stop methotrexate (4 patients), switch methotrexate to anti-
TNF agent (1 patient), stop budesonide (2 patients), and stop anti-TNF (1 patient); one patient 
was withdrawn from the trial because of the pregnancy. One patient was asked to temporary 
stop the treatment with 6-mercaptopurine by the fertility specialist prior the semen collection 
for in vitro fertilization. Three patients stopped their medication when they became pregnant, 
without consulting the physician (two patients were using azathioprine and one mesalazine). 
After having consulted the gastroenterologist, both patients who were previously using azathi-
oprine restarted the treatment.
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table 1. Patients` characteristics
total nr. of Patients 61
Females/males 51/10
Average age; years (min-max) 31 (20-52)
crohn`s Diseaes/Ulcerative colitis 40/21
crohn`s Disease Phenotype
 Luminal 38
  Small bowel localization 7 (17.5%)
  Ileocecal localization 7 (17.5%)
  Small and large bowel localization 17 (42.5%)
  Upper gastrointestinal involvement 0
  Large bowel localization 7 (17.5%)
 Fistulizing 2 
Ulcerative colitis Phenotype
 Pancolitis 12 (57%)
 Left-sided colitis 7 (33%)
 Proctitis 2 (10%) 
table 2. Medication of female IBD patients with active conception plans/pregnant
type of medication nr of patients (%) FDA category
  total n=51 
no medication 13 (25%) N/A
mono-therapy 36 (71%)
 5-aminosalicylates 9 B
 systemic steroids 2 C
 budesonide 2 C
 thiopurines 10 D
 methotrexate 3 X
 anti-TNF (infliximab/adalimumab) 9 (3/6) B
 study medication 1 N/A
combination therapy* 2 (4%) N/A
*one patient infliximab and azathioprine; one patient azathioprine and mesalazine
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table 3. Medication of male IBD patients with active conception plans
type of medication nr of patients 
  total n=10 
no medication 0 
monotherapy 8
 5-aminosalicylates 1 
 systemic steroids 1 
 budesonide 0 
 thiopurines 2 
 methotrexate 2 
 anti-TNF (infliximab/adalimumab) 2 (1/1) 
combination therapy* 2 
*one patient infliximab and prednisone; one patient infliximab and azathioprine
Figure 1. The medication used by IBD patients with active reproductive wish.
In total 57 patients on monotherapy are included and used for the calculation of percentages. 
In addition, four patients were on the combination therapy (2 patients on infliximab and azathi-
oprine, one patient prednisone and infliximab and one patient infliximab and mesalazine). 
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2% - Study medication
23% - None
19% - 5-ASA
19% - Thiopurines
Systemic steroids - 5%
Budesonide - 4%
Anti-TNF - 19%
Methotrexate - 9%
DIScUSSIOn
In the present study, we report the actual medication use in inflammatory bowel disease 
patients with active reproductive wish. First, we found that the majority of the patients with 
active reproductive wish require medication for which limited information on the safety of the 
peri-conceptional use is available. Second, we found that in one third of these patients the me-
dication was changed due to the active reproductive plans.
The first part of our observation helps to define the extent of the issue of medication use 
by IBD patients at fertile age. Only a minority of these patients did not require any medication 
(23%), or were using monotherapy with 5-aminosalicylates (19%), medication that has been 
shown to be safe in the peri-conceptional period6-8. In total, nearly half of the patients were 
using anti-TNF agents or immunosuppressive agents. Anti-TNF agents seem to be relatively safe 
as also reflected by their FDA categorization B. However, one must keep in mind that only short 
term observations9 are available for these therapeutics so far. In addition, the safety of the use 
of anti-TNF medication during the last trimester is still questionable due to the transfer of anti-
TNF through the placenta10,11. The uncertainty about the safety of the use of anti-TNF during 
pregnancy is also reflected in the recently reported survey on anti-TNF use. In this French natio-
nal survey, in one third of patients who became pregnant on anti-TNF therapy the therapy was 
stopped by the treating physician12. Since a substantial proportion of the patients in our study 
(19%) were using anti-TNF agents, we believe that gastroenterologists should actively identify 
patients on anti-TNF treatment with conception plans in order to provide the right counseling 
prior conception.
One quarter of the IBD patients with active reproductive wish were using immunosuppres-
sive agents, thiopurines or methotrexate. Thiopurines, although generally categorized as FDA 
category D have been shown to be safe at the dose used for IBD13. The experience with thiopu-
rines is longer than with anti-TNF agents, however, specific data on the long-term effects of the 
peri-conceptional and/or intrauterine exposure are not available. The original reports of conge-
nital malformations resulting from intra-uterine exposure were not confirmed in IBD patients. 
Nevertheless, the relative contra-indication for the peri-conceptional use of thiopurines is still 
mentioned in general information provided by the manufacturer. This often leads to confusion 
in IBD patients as also demonstrated by our two patients who stopped thiopurines when they 
became pregnant. The second type of immunosuppressive medication used by our patients, 
methotrexate, is absolutely contra-indicated in the peri-conceptional period due to its terato-
genicity and embryotoxicity14. Based on this information on peri-conceptional safety of immu-
nosuppressive agents, keeping in mind that important part of patients with active conception 
wish use this medication, we again would like to underline the necessity of pre-conceptional 
counseling for these patients. 
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In addition, few patients with active reproductive wish in our study were on combination the-
rapy. The risks of combination therapy are rather difficult to estimate. Therefore, in our opinion, 
these patients necessitate a careful coaching, with extensive discussion of the potential risks 
with the mothers/fathers-to-be.
In the second part of our analysis we found that one third of the patients eventually required 
a change of medication for reasons of their conceptions plans. Reproductive wish represents 
thus an important factor influencing the therapeutic strategy in IBD patients. Nevertheless, in 
our study, one third of patients did not consult their reproductive plans with the physician 
prior to the conception. This represents an additional argument for the above advocated active 
approach of the gastroenterologists in identifying IBD patients with active conception wish. 
Our data clearly indicate the importance of the reproductive issues in the management of IBD 
patients. It is presumable that without proper coaching many patients with active reproductive 
wish would finally choose for voluntary childlessness out of fear for the side-effects of the me-
dication on the child, as reported recently1. 
The results of the present study are potentially limited by reporting and selection biases. 
The first implies that the use of medication, in particular when potentially harmful, may act as 
incentive for patients to report their reproductive plans. However, the explicit question about 
the reproductive plans was asked by the treating physicians during the outpatient consultation 
which would lower the risk of underreporting. Concerning the selection bias, a typical referral 
center IBD population is characterized by complicated disease course and therefore also more 
frequent use of immunosuppressives15 which also applies for our group of patients.
Thus, reproductive wish represents an important factor influencing the therapeutic strategy 
in inflammatory bowel disease patients. This underlies the necessity of active approach with 
regards to the reproductive issues in these patients in everyday practice. Two-thirds of patients 
proceed to achieve pregnancy under the medication of unclear safety in this setting. Therefore, 
the information from post-marketing studies on the peri-conceptional safety of the novel me-
dications used in IBD will be extremely valuable in the management of these patients.
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LeTTer To ediTorS
Dear sir,
We read with interest the article by Christensen et al.1 demonstrating a low penetration of 
6-mercaptopurine (6-MP) in maternal milk of eight inflammatory bowel disease (IBD) patients 
on azathioprine. Based on this reported low exposure of children to azathioprine (<1% of the 
maternal dose), breastfeeding during azathioprine therapy seems safe.
This study is of great importance as little is known about breastfeeding by IBD patients 
on azathioprine. However, considerable inter-individual variability in the absorption and 
metabolism of azathioprine2, 3 makes it difficult to predict whether this very low dose in maternal 
milk would not eventually result in a clinically relevant cumulative dose in the individual child. 
Therefore, we propose to monitor the azathioprine metabolites levels in the breastfed child as 
studied earlier4. We would like to demonstrate the feasibility of this approach in the case of a 
child born to a 31-year old mother with Crohn`s disease. The child was fed with maternal milk 
during 3 months, while the mother was treated with azathioprine, 100mg a day (1.4mg/kg). At 
day 8 of the breastfeeding, the peripheral blood levels of 6-methylmercaptopurine (6-MMP) 
and 6-thioguaninenucleotides (6-TGN) were assessed in the child, both appeared undetectable. 
At month 3, when the feeding with maternal milk was tapered to zero, the levels of 6-MMP and 
6-TGN were again undetectable in the child whilst the mother had therapeutic levels (6-MMP 
410 pmol/108 red blood cells, 6-TGN 470 pmol/108 red blood cells). During the six months of the 
follow-up, the child thrived and did not suffer from any infections.
Thus, breastfeeding by IBD patients on azathioprine is probably safe. However, until more 
experience is gained, we advocate the monitoring of azathioprine metabolites as a doable 
method to safeguard the minimal exposure of a breastfed child. 
Best regards, 
Zuzana Zelinkova, MD
Department of Gastroenterology&Hepatology
Erasmus MC, Rotterdam, The Netherlands
Inge P. de Boer, MD
Department of Pediatrics
Diakonessenhuis, Utrecht, The Netherlands
Mirian J. van Dijke, MD
General Practitioner, Utrecht, The Netherlands
Ernst J. Kuipers, MD
Department of Gastroenterology&Hepatology
Erasmus MC, Rotterdam, The Netherlands
C. Janneke van der Woude, MD
Department of Gastroenterology&Hepatology
Erasmus MC, Rotterdam, The Netherlands
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ABStRAct
Background
Lactation during the thiopurine therapy seems to be safe as thiopurines are excreted through 
breastmilk only in a very low concentration. However, it is unclear whether interindividual 
pharmacokinetic and pharmacodynamic differences cannot lead to the accumulation of the 
thiopurines metabolites with potential of toxic side-effects, namely myelosuppression in the 
newborn. Therefore, we proposed earlier the monitoring of the thiopurine metabolites in 
the child as a doable method to safeguard the safety of lactation during the treatment with 
thiopurines. Here, we report the results of the first five patients monitored according to this 
protocol.
methods
Pregnant inflammatory bowel disease (IBD) patients using azathioprine were given 
the information about the monitoring of the lactation safety during the treatment with 
azathioprine. In case they wanted to breastfeed, the levels of 6-methylmercaptopurine (6-MMP) 
and 6-thioguaninenucleotides (6-TGN) were measured in the peripheral blood of the child 
during the second week of the breastfeeding and, when appropriate, at month 3. 
Results
Five children born to mothers treated with azathioprine were breastfed and the levels of 
6-MMP and 6-TG were assessed during the second week of the full breastfeeding. None of the 
newborns had detectable levels at this point; in two children the levels of 6-TGN and 6-MMP 
were assessed again in the 3rd month of life and were again undetectable. 
conclusion
Lactation during the use of azathioprine does not lead to accumulation of the azathioprine 
metabolites in the newborn. However, until this approach is validated in a larger cohort, we 
advise to continue the monitoring of the thiopurines metabolites levels in the newborn.
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IntRODUctIOn
Thiopurines (azathioprine AZA and 6-mercaptopurine 6-MP) are used widely for the induction 
and maintenance of remission of inflammatory bowel disease (IBD). IBD affects typically young 
patients with family plans and therefore, the questions on the safety of the use of these drugs 
during pregnancy and lactation are frequently encountered in the clinical practice. The exposure 
of the foetus to low levels of the end-metabolites of thiopurines, 6-thioguaninenucleotides 
(6-TGN), documented recently5, 6 does not seem to lead to unfavourable pregnancy outcomes 
in terms of teratogenicity7. Thus, for the use of thiopurines during pregnancy of IBD patients 
the benefits of controlled disease are considered to outweigh the risks for the child and the 
continuation of this treatment during pregnancy is recommended8. 
Once the child is born, the question arises of the safety of the use of these drugs during 
lactation. In contrast to the data on pregnancies, the effect these drugs may have on the child 
through lactation is much less studied. Thiopurines seem to have a very low penetration in the 
breast milk, as it has been demonstrated by the measuring of 6-MP levels in maternal milk of 
eight IBD patients on azathioprine1. Based on this report, breastfed children by mothers using 
thiopurines would be exposed to a very low dose of the thiopurine metabolites corresponding 
to less than 1% of the maternal dose1. This finding suggesting safety of the thiopurine use 
during lactation has been further supported by measurements of thiopurine metabolites in 4 
children breastfed by mothers using azathioprine that showed absence of these metabolites in 
peripheral blood of the infants4. Thus, the use of thiopurine by breastfeeding women with IBD 
seems to be safe for the child.
Nevertheless, these reports are very limited in size. In addition, the dose of azathioprine used 
by mothers in the referred study on the thiopurines excretion in the breast milk1 was in 5 out 
of 8 patients included lower than the recommended dose for the use in IBD, i.e. 2-2.5mg/kg, 
which makes it difficult to apply these results for larger patient population. Furthermore, one 
must keep in mind that there is a considerable inter-individual variability in the absorption 
and metabolism of azathioprine2, 3. This variability makes it difficult to predict whether the 
documented very low dose of thiopurine metabolites in maternal milk would not eventually 
result in a clinically relevant cumulative dose in the individual child. Therefore, we proposed 
earlier the monitoring of the thiopurine metabolites in the child as a doable method to 
safeguard the safety of lactation during the treatment with thiopurines9. Here, we report the 
results of the first five patients monitored according to this protocol.
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mAteRIALS AnD metHODS
Pregnant IBD patients using AZA were recruited from the outpatient IBD clinic specifically 
dedicated to pre-conceptional counselling of IBD patients. At the consultation, the current 
safety data on the breastfeeding during AZA therapy were explained to the patients. More 
specifically, they were given information that according to thus far published studies the use 
of AZA during lactation is probably safe but that the numbers of patients documented in 
this setting are limited. In case that wanted to breastfeed, they were offered the possibility 
of measuring the levels of 6-MMP and 6-TGN in the peripheral blood of the child during the 
second week of the breastfeeding. At the same time, maternal levels of 6-MMP and 6-TGN were 
assessed.
ReSULtS
In total, 6 patients on azathioprine treatment wanted to breastfeed, one patient did not want 
to measure the 6-MMP and 6-TGN levels in her child; she was breastfeeding during the period of 
one year and the child thrived well. Remaining five patients consented to assess the 6-MMP and 
6-TGN levels in their children, all of them had undetectable levels of these AZA metabolites. The 
6-MMP and 6-TGN levels of 3 mothers and all five children are shown in Table 1.
table 1. 6-methylmercaptopurine (6-MMP) and 6-thioguaninenucleotides (6-TGN) levels in 
the children and mothers
case Duration of the  Levels child** Levels mother** Dosis azathioprine mother
 breastfeeding*  
1 7 days undetectable 6-TGN 110 150 mg/day
   6-MMP 580 
2 7 days undetectable Not assessed 200 mg/day
3 1 month undetectable Not assessed 150 mg/day
4 8 days undetectable 6-TGN 470 100 mg/day
 3 months undetectable 6-MMP 410 
5 8 days undetectable 6-TGN 170 150 mg/day
 3 months undetectable 6-MMP 7150 
* at the moment of the assessment of the 6-MMP and 6-TG levels in the child 
** pmol/108 red blood cells
DIScUSSIOn
We report here the first results of the monitoring of thiopurines metabolites levels in five 
children breastfed by IBD patients treated with azathioprine. In none of the children, these 
levels were detectable which is in line with previous report using this monitoring method4. 
So far, there were no cases of documented exposure of children to thiopurines in this setting. 
Furthermore, a recent report on the long term follow-up of 15 children breastfed for a median 
period of 6 months by mothers using AZA showed a normal development of these children 
during the follow-up of up to 4 years without an increased risk of infections10. Thus, both 
pharmacokinetic studies and clinical follow-up suggest that the use of AZA during lactation is 
safe for the child.
However, in all these studies, the maternal dose of AZA was rather low, which corresponded 
with suboptimal therapeutic levels of 6-TGN in mothers in our study and low therapeutic levels 
in the report by Christensen1. It has been documented that levels of 6-TGN vary greatly during 
pregnancy6 and this is also likely to be the case in the post partum period during which the 
maternal organism undergoes important changes in distribution volume and body weight. In 
addition, inter-individual differences in AZA metabolism in adults are well recognized2, 3 which 
makes it difficult to use the results of these limited size studies for general recommendations. 
Furthermore, it has been shown that, compared with adults, neonates have higher activity of 
thiopurine S-methyltransferase (TPMT), an enzyme that plays crucial role in the metabolism 
of thiopurines11. This illustrates clearly, why the predictions on the pharmacokinetics in the 
neonates cannot be made using the calculations derived from data obtained in adults. Thus, 
the variability of thiopurine pharmacokinetic on maternal side together with specificities of the 
thiopurine metabolism in the first months of life can both influence the final cumulative dose 
to which the child will be exposed.
Therefore, we believe, the available evidence does not allow general recommendations on 
the use of azathioprine during lactation without careful monitoring of the child, ideally by the 
means of measurements of thiopurine metabolites levels at two different time points during 
the first months of lactation.
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Chapter 7
High Intra-Uterine Exposure to Infliximab Following Maternal 
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ABStRAct
Background 
Typically, inflammatory bowel disease (IBD) patients are in their reproductive years, raising 
questions about safely using anti-tumor necrosis factor antibodies like infliximab (IFX) during 
pregnancy. IgG antibodies naturally cross the placenta, especially during the last trimester. To 
prevent fetal intra-uterine exposure, stopping IFX treatment at gestational week 30 is recom-
mended. However, whether this limits intra-uterine and early post-natal IFX exposure is une-
stablished. 
Aim
To determine the intra-uterine exposure to IFX following maternal treatment with IFX.
methods
Four pregnant IBD patients intentionally continued IFX during pregnancy. IFX levels were 
assessed in newborns’ cord blood and the mothers’ peripheral blood at delivery. The children’s 
development during the first 3–6 months, infections, vaccine reactions and antibody responses 
to vaccinations against Haemophilus influenzae type b and Pneumococcus were assessed.
Results
The patients stopped IFX therapy at gestational week 21, 26, 26, and 30, respectively. In three 
infants, therapeutic IFX levels were present in cord blood at levels of 5.5–13.7 μg/mL and were 
two- to three-fold higher than in the peripheral blood of their mothers. During the 3–6-month 
follow-up, the children developed normally without signs of infections or allergic reactions, and 
had normal antibody titers after routine childhood vaccinations. 
conclusion
The use of IFX until gestational week 30 leads to fetal intra-uterine exposure to IFX at le-
vels that exceed those in the mothers’ peripheral blood. Although no short-term complications 
were detected, the high IFX levels observed in newborns raise concerns about unknown effects 
of IFX on the developing immune system. 
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IntRODUctIOn
Anti-tumor necrosis factor (anti-TNF) agents are frequently used powerful immunomodulatory 
agents available to clinicians to treat several autoimmune conditions including inflammatory 
bowel disease (IBD). Potential candidate patients for anti-TNF treatment are often young and 
in their reproductive years, which is also reflected in the observation that 20% of IBD patients 
with active reproductive wishes require treatment with anti-TNF agents1. Therefore, the safety 
of anti-TNF use during conception and pregnancy has become a major concern for patients and 
their clinicians.
Of the various anti-TNF agents, infliximab (IFX), a chimeric monoclonal antibody against TNF, 
is the best characterised with respect to safety during human reproduction. Short-term data 
from two safety registries found no important teratogenicity issues2,3. However, intra-uterine 
exposure to IFX resulting from placental antibody transfer was previously reported in children 
born to mothers treated with IFX during pregnancy4,5. Like all IgG antibodies, IFX crosses the 
placenta beginning in the second trimester, probably reaching its maximal transport capac-
ity during the third trimester6. To limit this placental transfer stopping IFX treatment prior to 
gestational week 30 was proposed7,8. Nevertheless, in view of the strong immunomodulatory 
properties of IFX and the lack of long-term outcome data, the safety of terminating IFX therapy 
at gestational week 30 is difficult to take for granted without data showing that this is sufficient 
to prevent transfer of significant amounts of anti-TNF to the unborn child. 
Concern about the unpredictable outcomes of early exposure of the developing immune 
system to powerful TNF-alpha neutralization and the immunomodulatory potential of anti-TNF 
molecules is, at least on a theoretical basis, substantial. This concern, together with an absence 
of data in which the level of IFX transfer to the unborn child is actually assessed following ter-
mination of anti-TNF therapy during different gestational weeks, prompted us to determine 
the exposure of the newborn to IFX in this case series of four IBD patients intentionally treated 
with IFX until gestational week 30. We found that this approach is not sufficient to limit the 
placental transfer of IFX, resulting in IFX levels in the cord blood that exceed the therapeutic 
level for adults.
PAtIentS AnD metHODS
Four patients (three with Crohn`s disease and one with ulcerative colitis, aged 19, 29, 29, and 
31 years, respectively) were intentionally treated with IFX during pregnancy. All patients con-
tinued the remission-maintaining preconception dose regimen. In one patient, methotrexate 
was advised to be discontinued following her expressed wish to reproduce. Three patients were 
receiving IFX at a stable dose of 5 mg/kg every eight weeks, and one patient received 10 mg/kg 
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every eight weeks. Two patients had periconceptional IFX monotherapy, one patient was using 
azathioprine. The patient using methotrexate conceived within two months after stopping 
methotrexate and continuing IFX monotherapy. The other three patients had stable medica-
tion during the six months prior to conception. One patient stopped IFX at gestational week 
21, two patients at week 26, and one patient at week 30. The respective gestational weeks at 
delivery are shown in Table 1. The decision of discontinuation of IFX was at the discretion of 
treating gastroenterologist who discussed all pros and cons of the treatment continuation with 
the patients at an early stage of their pregnancy. The timing of discontinuation was motivated 
by the current approach advising not to extend the use of IFX beyond 30 weeks of pregnancy. 
The exact date of the last infusion was based on the 8-weeks schedule with which patients 
entered the pregnancy so that the last infusion would be given prior or at the week 30 at the 
latest. At delivery, cord blood was collected from the newborns, and peripheral blood serum 
was obtained within two days after delivery from the patients. 
All children received routine childhood vaccinations according to recommendations in the 
Netherlands, i.e. a combined vaccine for diphteria, tetanus, pertussis, and polio; Haemophilus 
influenzae b; and pneumococcus at the ages of 2, 3, and 4 months. The response to bacterial 
vaccines was assessed at month 6 of life in two of the three children born with significant IFX 
levels. 
The IFX serum levels were measured by ELISA, the assay has been adapted and validated in 
our laboratory based on the previously reported and validated assay9. High binding capacity 96-
well ELISA plates (Nunc-ImmunoTM Plates) were coated overnight at 4°C with 50µl of 2µg/mL 
recombinant human TNF-alpha (Invitrogen) diluted in phosphate buffered saline (PBS). The 
plates were washed twice with PBS 0.05% Tween 20 (PBST). The remaining protein-binding sites 
were blocked during two hours at room temperature with 250µl of 3% non-fat dry milk (Elk 
Campina, Eindhoven, The Netherlands) diluted in PBST. The plates were washed five times with 
PBST and 100µl of serum, standard and control samples were added. For the negative control, 
a pooled human serum, obtained from random 40 different healthy individuals was used. To 
generate standard curve, serial concentrations of infliximab (Remicade®, Merck Sharp&Dohme) 
were used. The serum samples were serially diluted at concentrations of 1:1000 to 1: 32000. All 
samples were diluted in PBST containing 1% bovine serum albumine (BSA). The samples were 
incubated during one hour at room temperature and subsequently washed four times with 
0.05% PBST. The reaction was revealed using 100µl of 3,3’,5,5’tetramethylbenzidine (eBiosci-
ence) solution at room temperature and stopped with 100µl of 1M H2SO4. Reading was per-
formed at two wave lengths; 450 and 620 nm using Biorad 680 plate reader. The samples were 
run in different concentrations as mentioned above and the final infliximab serum concentra-
tions were interpolated from the standard curve. The results were rejected if difference between 
the calculated concentration of the serial dilution was higher than 20%, and the accepted mea-
surements were considered as triplicates to calculate the mean. 
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The assay was tested and validated using serum samples from patients receiving IFX and 
those who were naïve to this drug. For the average inter-assay coefficient of variation calcula-
tion, 10 samples were run on different days and the standard deviation per patients sample was 
expressed as a percentage of the mean. The average inter-assay coefficient was 4%. The inter-
assay coefficient was calculated using the serial dilutions of samples that were used instead of 
triplicates. For this calculation 3 dilutions of 10 samples were measured with the intra-assay 
variability coefficient of 4.4%. 
Since the treatment protocol is considered a standard care, no approval of ethical committee 
has been solicited.
ReSULtS
Pregnancy outcomes
Patients gave birth at gestational weeks 37, 36, 41, and 38, respectively (Table 1). Three 
children were healthy without congenital malformations. One baby girl, born to a 19 year old 
mother (patient Nr 3), experienced respiratory depression after birth owing to anesthetics 
used during delivery, and which resolved spontaneously. This child was also diagnosed with 
polydactyly of her left hand. Apart from infliximab, the mother had used methotrexate till two 
months prior to conception and had omitted to use the recommended folic acid supplemen-
tation during the first weeks of the pregnancy. Other risk factors for congenital malformations, 
such as alcohol consumption, smoking or consanguinity were not revealed.
During the follow-up of 4 to 11 months, all children developed normally, there were no signs 
of infections, and no abnormal reactions to vaccinations were observed. The antibody response 
to vaccinations against pneumococcus and Haemophilus influenzae b were assessed in two of 
the three children born with detectable IFX levels. Both children had protective levels of vacci-
ne antibodies when checked at month 6.
IFX levels
Only one patient (patient 1) had undetectable levels of IFX in her peripheral blood at delivery 
and undetectable levels in her infant’s cord blood. This patient received her last IFX infusion at 
gestational week 21. In three other patients, therapeutic levels of IFX were found in the cord 
blood at levels of 13, 5.5 and 13.7 μg/mL, respectively. The levels in cord blood were higher than 
the levels measured in peripheral blood of mothers (p=0.032 with one-tailed paired t-test), 
which were 4.9, 2.4, and 5 μg/mL respectively. 
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Patient follow-up 
All four IBD patients remained in remission throughout their pregnancy and resumed IFX 
treatment within 4 weeks after delivery. The re-treatment with IFX did not result in allergic 
reactions and all patients remained in remission during the 4 to 11 months of follow-up after 
delivery. 
table 1. Pregnancy outcomes and medication during pregnancy
 Patient Infliximab co- Infliximab stopped Gestational Birth congenital
 number dose medication (gestational week) week delivery weight (g) malformations
 1 5 mg/kg,  None 21 37 2650 none
  every 8 weeks  
 2 5 mg/kg,  None 26 36 4030 none
  every 8 weeks 
 3 5 mg/kg, None* 26 41 3030 Polydactyly 
  every 8 weeks     left hand
 4 10 mg/kg,  Azathioprine 30 39 3185 none
  every 8 week 2 mg/kg  
*Methotrexate two months prior to conception 
Figure 1. Infliximab levels in cord blood of newborns (black bars) and in the peripheral blood 
of the mothers (grey bars) at delivery. In the three patients with detectable IFX levels, the levels 
in newborn were higher than the levels at the peripheral blood of the mothers (one-sided pa-
ired t-test, p=0.032)
* Levels undetectable 
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DIScUSSIOn
In this case series, we show that the currently advocated approach of stopping IFX at gesta-
tional week 30 does not prevent the intra-uterine exposure of the fetus to significant levels of 
IFX. This finding is important in clinical practice because of the potential short-term as well as 
long-term complications of early exposure to anti-TNF.
Data from the safety registries2,3, as well as a recently published first prospective cohort on 
the outcomes of pregnancies exposed to infliximab10 did not reveal significant teratogenicity 
issues.  In one out of the four patients presented in our study, polydactyly of the hand was dia-
gnosed in a child born to a mother using IFX at conception and during the first two trimesters 
of the pregnancy. However, this patient also conceived only two months after stopping metho-
trexate. Digital malformations have been reported with the use of methotrexate but almost 
exclusively in combination with other birth defects11 which were not present in this child. To our 
knowledge, no isolated polydactyly has been reported in the case of the pre-natal exposure to 
infliximab. In addition, polydactyly is a very common birth defect in general population12. Thus, 
no clear association with the medication can been concluded, however, the role of the pre-con-
ceptional use of methotrexate remains a subject of discussion in this patient. 
Intra-uterine exposure to IFX of children born to mothers receiving IFX treatment was first 
suggested by Vasiliauskas et al. in 20064. In this case report, the mother used IFX during the en-
tire pregnancy, and clinically significant levels of IFX were detected in the child’s serum sample. 
The hypothesis of placental transfer of IFX was further supported by a study by Mahadevan et 
al.5 where authors reported clinically significant levels in the cord blood of the infant and serum 
samples taken directly postpartum from five children born to mothers treated with IFX. In this 
case series, the mean time between birth and last IFX infusion was 30 days. Kane et al.13 measu-
red the levels of IFX in two children born to mothers treated with IFX until gestational week 32 
and 24, respectively. In both children, IFX was undetectable; however, the samples were taken 
postpartum on days 15 and 57, respectively, which makes the assumption of a lack of intra-ute-
rine and early postnatal exposure to IFX uncertain.  
The kinetics of IgG antibodies in general are governed by the neonatal Fc receptor (FcRn)14. 
Antibodies are passively taken up by endothelial cells among other cell types and subsequ-
ently sequestered through binding to intracellularly expressed FcRn then shuttled back to the 
extracellular milieu. This recycling helps to increase the life time of the antibodies by protecting 
them from catabolism15. The same mechanism is used by maternal IgG antibodies that cross the 
placenta beginning in the second trimester16. IFX, being an IgG1 class antibody with a functi-
onal Fc, very probably crosses the placenta in the same way17 and is subject to the efficient 
FcRn-mediated protection from break down in the newborn. The biological half time of IFX 
in the newborn is also expected to be longer than in adults because of the high expression of 
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the FcRn during the first months of life. Indeed, the series of 5 children born with detectable 
IFX levels showed the persistence of IFX in the peripheral blood of the children for as long as 6 
months5. Thus, the placental transfer of IFX not only raises the issue of intra-uterine exposure 
but, most importantly, the concern about consequences for immune system functioning and 
development during the first weeks of life. 
Children born with detectable levels of IFX do not seem to have an increased risk of infecti-
ons in their first year of life and have normal responses to vaccinations with bacterial non-live 
vaccines. This was documented in the eight-patient series reported by Mahadevan et al.18 and 
is also supported by the findings in the current study. However, a fatal case of disseminated 
mycobacterial infection after BCG administered at month 3 to a child born to a mother treated 
with IFX during the entire pregnancy was recently reported19. In this case, the likely mechanism 
of insufficient immune control of the live attenuated vaccine would be the neutralization of 
TNF-alpha by IFX, although no measurements of IFX levels in the child were performed. The 
specific infectious complications resulting from the use of anti-TNF agents are well known and, 
therefore, vaccinations with live antigens are also prohibited in patients on anti-TNF treatment. 
Because significant levels of IFX may persist for several months in children born to mothers 
treated with IFX, vaccinations with attenuated vaccines should be postponed until IFX levels 
are undetectable. 
Early exposure of the immune system to powerful TNF-alpha blockade also raises concerns 
about the long-term consequences for the maturation of the immune system. In the context 
of the increasing number of reports of hepatosplenic T-cell lymphoma in young adolescents 
treated with combined immunosuppressive therapy containing, in most cases, anti-TNF20, and 
keeping in mind the lack of long-term outcome data, we believe the actual approach should be 
to try to limit the intra-uterine and postnatal exposure of children to anti-TNF in general.
The decision to stop treatment with a drug that keeps the mother’s underlying disease in 
remission during pregnancy is a difficult decision for the treating physician. A disease flare may 
represent a substantial risk not only for the patient, but also for the unborn child. On the other 
hand, in the absence of convincing long-term safety data of the perinatal exposure to IFX, the 
continuation of the treatment remains a subject of discussion. Simultaneously, the decision to 
stop IFX is difficult in the current absence of predictors for the disease course during pregnancy 
in this specific setting. In addition, in case of treatment with anti-TNF, allergic reactions during 
retreatment which had been postponed for more than 12 weeks represent another concern. In 
this limited series of patients, we did not observe any of these problems; all patients remained 
in remission after stopping IFX and no allergic reactions occurred during retreatment after de-
livery. Our observation is also supported by the results of the first prospective cohort of 35 IBD 
patients treated with IFX during first two trimesters of the pregnancy that did not show nega-
tive impact of this approach nor on the disease course neither on the pregnancy outcomes10. 
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Interestingly, in three patients with detectable levels of IFX at delivery, the interval between the 
last IFX infusion was 10, 15, and 9 weeks, respectively. The elimination half-time of IFX for wo-
men being 18 days21, one would expect no detectable levels in these patients at delivery. That 
these patients still had detectable levels of IFX may indicate changes in the pharmacokinetics 
of IFX during pregnancy that would lead to a longer biological half-life of IFX and, therefore, 
possibly may provide a safe way to stop treatment earlier in the pregnancy. 
In conclusion, the use of IFX at the end of the second trimester of pregnancy leads to intra-
uterine exposure of the fetus to IFX. This exposure does not seem to have a negative impact on 
the child in terms of increased infection rate and vaccination failure, but in specific situations, 
such as vaccinations with attenuated live antigens, the presence of IFX may have fatal consequ-
ences. Therefore, we propose that the levels of IFX be assessed in every child born to mothers 
treated with IFX during pregnancy, and to administer attenuated live vaccines only to children 
with undetectable IFX levels. Additionally, the long-term effects of this early exposure of the 
immune system to IFX are hard to predict. Therefore, for patients in whom the quiescent disea-
se during pregnancy allows interruption of treatment, intra-uterine and postnatal exposure of 
newborns to IFX may probably be avoided by stopping IFX at the beginning of the second tri-
mester. In order to determine the exact timing of the discontinuation of IFX during pregnancy, 
further studies on the pharmacokinetics in this setting need to be conducted.  
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Chapter 8
Effect of Adalimumab on Semen Quality in Inflammatory 
Bowel Disease Patients
Zuzana Zelinkova, Cokkie van der Ent, Ernst J Kuipers, Gert R Dohle, C Janneke 
van der Woude 
ABStRAct
Background
Inflammatory bowel diseases (IBD) patients are typically in their reproductive years. Therefore, 
the frequently encountered clinical problem concerns the impact of the disease and therapy 
on the IBD patients` fertility. Adalimumab (ADA) represents a recently introduced therapeutic 
effective in IBD. The wide-spread use of ADA, including IBD patients with active conception wish 
raises the question of its effect on the semen quality and outcomes of pregnancies conceived 
by males under ADA treatment.
Aim
First, the aim of this study was to assess the influence of ADA on the semen quality of IBD 
patients using ADA. Second, we analysed the outcomes of the pregnancies conceived under 
the use of ADA by male IBD patients. 
methods
Male IBD patients naïve to ADA and planning to start the treatment with ADA were included. 
The semen sample was obtained prior to starting the treatment, at month 3 and at month 6 of 
the treatment. The semen quality according the WHO criteria was assessed and the influence 
of ADA on the semen quality was evaluated intra-individually. In addition, the patients who 
became fathers during the treatment with ADA were identified at the outpatient clinic during 
their regular consultation and outcomes of these pregnancies were assessed.
Results
The effect of the treatment with ADA on the semen quality was assessed in seven IBD patients. 
No differences in the sperm concentration, percentage of cells with progressive motility and 
cells` vitality were found between the baseline samples and samples obtained at month 3 and 
6 during the treatment.
In addition, two patients conceived during the treatment with ADA. Both children were born 
à terme, without congenital malformations.
conclusion
In this small sample size inflammatory bowel disease patients` group, we did not observe any 
modifying effect of adalimumab on the semen quality.
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IntRODUctIOn
Inflammatory bowel disease (IBD) represents a chronic inflammatory disorder affecting 
gastrointestinal tract. The patients necessitate lifelong follow-up and intensive medical and/
or surgical treatment. As the disease typically affects patients in their reproductive years, 
procreation represents a frequently encountered issue in the clinical practice. Reproduction 
of IBD patients is influenced by two overlapping factors, disease itself and the therapeutic 
interventions. In males, many factors interfere with the sperm quality and subsequent fertility, 
such as fever and/or presence of an inflammatory condition. Therefore, in order to enhance the 
chances for successful conception it is important to keep the disease under control.
Inherently, the issue of the safety of the use of a particular medication by the fathers-to-
be becomes an important question in the clinical practice. In the past years, the field of IBD 
therapeutic has undergone a dynamic evolution with the introduction of new therapeutic 
agents, biologicals directed against human tumor-necrosis alpha (anti-TNF). To date, two 
distinct anti-TNF agents have shown their efficacy in the treatment of IBD, infliximab (IFX)1, 2 
and adalimumab (ADA)3, 4. Thus far, very limited data are available on the safety of the use of 
anti-TNF agents by men with IBD who wish to conceive. Keeping in mind the limitations of small 
sample size, the periconceptial use of IFX by male patients is probably safe5, 6 but no data are 
available on ADA use by future fathers. 
Therefore, in the present study we aimed at filling this gap by first, studying the impact of the 
ADA treatment on the semen composition and second, to analyse the outcomes of pregnancies 
conceived under indirect exposure to ADA. We found no alterations of the sperm quality 
induced by the treatment and favourable outcomes of pregnancies identified retrospectively 
as indirectly (i.e. through male exposure in the peri-conceptional period) exposed to ADA. 
PAtIentS AnD metHODS
Between October 2009 and April 2011, male IBD patients planning to start treatment with ADA 
were recruited from the IBD outpatient clinic of the Erasmus MC. A semen sample was collected 
before the start of treatment, and subsequently at month 3 and month 6 of the treatment. At 
the initiation of treatment with ADA, induction regimen of 160 mg s.c. at week 1,80 mg at week 
3 was applied and subsequently patients continued the maintenance medication of 40 mg 
every other week. The quantitative and qualitative semen samples analysis was performed 
according to the WHO criteria7.
Before each sampling the disease activity was assessed by CDAI and the co-medication 
was noted, together with the information on the smoking habits and alcohol use. The co-
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medication had to remain stable during the 6-months follow-up. To assess whether the impact 
of the disease or/and the treatment on the fertility is ensuing from a disturbed endocrine status, 
foliculi stimulating hormone, testosteron and inhibine-B levels were measured. Medical ethical 
committee approval was obtained for this part of the study and all patients were included after 
informed consent had been obtained.
In addition, all pregnancies conceived during ADA treatment were retrieved. The patients 
attending the IBD outpatient clinic treated with ADA were asked whether they conceived 
children during the treatment with ADA. The outcomes of these pregnancies – birth weight, 
gestational age at delivery and congenital malformations were obtained from the patients and/
or their partners.
ReSULtS
effect of adalimumab on sperm composition 
In total, 8 patients were included, all with Crohn`s disease, average age 32 years (range 
25-46); with the indication for ADA as follows: 6 patients luminal disease, one patient fistulising 
disease and one patient with extra-intestinal manifestations of arthritis. In terms of response 
to medication, six patients responded to treatment, one stopped ADA after 3 months due to 
non-responsiveness and one patient needed dose escalation to weekly dose of 40 mg. One 
patient dropped out and no semen samples at month 3 and 6 could have been obtained from 
him. In two patients no samples at month 6 were available for analysis, one patient stopped 
the medication and one wished to stopped the participation at the study. In seven patients, at 
least one of the follow-up samples under ADA treatment could have been analysed. From these 
seven patients, three patients had baseline abnormalities of the sperm composition regarding 
sperm concentration and/or motility; in two patients these abnormalities remained present 
during the treatment. 
Overall, no differences in semen volume, sperm concentration and motility (Figure 1), semen 
pH, agglutination and presence/absence of leucocytes induced by the treatment were noted. 
No abnormalities in the hormonal status were observed. 
Outcomes of pregnancies conceived under adalimumab treatment
Two pregnancies with indirect exposure to ADA were identified. Both children were born 
à terme, at respective gestational weeks 40 and 38, with birth weight of 3820 grams and 
2800 grams, and no congenital malformations.
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Figure 1. Changes in sperm concentration (Figure 1A) and progressive motility of sperm cells 
(Figure 1B) during the treatment with ADA as compared to baseline prior to treatment
DIScUSSIOn
In this small sample size Crohn`s disease patients` group, we did not observe any modifying 
effect of adalimumab on the semen quality as assessed by analysis of the sperm composition 
and outcomes of two pregnancies conceived while fathers were using adalimumab.
The concerns about the use of anti-TNF agents in male IBD patients with conception wish are 
related to two areas; first, to the impact of anti-TNF agents on fertility and second, the outcome 
of the pregnancies conceived under indirect exposure to anti-TNF.
To study these questions, there are several methodological possibilities including animal 
studies, in vitro experiments, human studies assessing the effect of anti-TNF agents on semen 
quality in vivo and clinical trials assessing the outcomes of pregnancies with indirect exposure 
to ADA. It has been shown in vitro that TNF-α inhibits germ cell apoptosis8 and in animals 
studies TNF-α effect on seminiferous epithelium survival has been effectively blocked by 
infliximab9. In a study with 10 male patients with different indications for infliximab treatment, 
decreased sperm motility but increased sperm concentration has been found after start of 
infliximab treatment10. Thus, there are indications that TNF-α may play an important role in 
spermatogenesis and that its proper functioning might be influenced by the systemic use of 
an anti-TNF agent. However, the animal studies are difficult to be interpreted with regards 
to the experiments testing a humanized and thus species-specific antibody and the human 
data available thus far are still limited to few patients. It is therefore important to study these 
questions using a relevant methodological design in human.
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Our study is the first study evaluating the effects of ADA treatment on sperm composition. 
The fact that we did not observe changes in semen composition after start of ADA treatment 
is reassuring and suggests that the interference of this particular agent with spermatogenesis 
would be minimal if not non-existing. However, these results must be interpreted with caution, 
keeping in mind that DNA damage does not necessarily need to be accompanied by changes 
in the microscopic appearance of sperm cells.
Therefore, a thorough identification, follow-up and subsequent reporting of all pregnancies 
with indirect exposure to ADA represents a crucial step towards final evaluation of the safety 
of ADA use by the future fathers. Thus far, no such cases have been documented and to 
our knowledge the two pregnancies we report here are the first indirectly exposed to ADA 
documented pregnancies. In line with the observation of lack of influence of ADA on the semen 
composition, both pregnancies we report here had favourable outcomes. However, the small 
sample size and retrospective character of identifying the cases call for caution in generalizing 
these observations. Nevertheless, these data helps to create the body of evidence serving the 
patients and their physician in the difficult decision-making once the reproductive issue comes 
up in a patient on an established therapy with ADA. 
Once a male IBD patient who wishes to conceive is on an established treatment, the 
discontinuation of the treatment might have disastrous consequences for his disease course. In 
order to really insure the conception with semen produced without any influence of the drug, 
one must take into account not only the biological half time of a particular drug, but also the 
duration of the spermatogenesis that takes 60 to 80 days. Thus, depending on the drug kinetics, 
the time needed to produce `drug influence free` sperm, can easily reach 4 to 6 months that 
patient needs to be off the drug. In this period, the patient carries important risk of relapse and 
in case of treatment with anti-TNF agents is also at increased risk of allergic reactions and loss of 
response once the treatment is resumed. Thus, it is important to realize, that also in males, the 
reproductive plans influence the therapeutic strategy in a substantial way.
In conclusion, our small sample size study suggests that there is not an important influence 
of adalimumab on the spermatogenesis. However, we do not feel that these small sample size 
data allow advocating of active peri-conceptional use of adalimumab by male IBD patients and 
extensive discussion should take place with the patient before he and his partner make their 
decision. 
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Chapter 9
Evaluation of the Discontinuation of Infliximab 
during Pregnancy in Inflammatory Bowel Disease Patients
Zuzana Zelinkova, Cokkie van der Ent, Karlien F Bruin, Onno van Baalen, Hestia G 
Vermeulen, Herman J Smalbraak, Rob J Ouwendijk, Aad C Hoek, Sjoers D van der Werf, 
Ernst J Kuipers, C Janneke van der Woude and The Dutch Delta IBD group
Submitted
ABStRAct
Objective
Discontinuation of infliximab (IFX) prior to the third trimester is recommended to limit early 
neonatal exposure to IFX. The aims of this study were first, to assess the course of inflammatory 
bowel disease during pregnancy after discontinuation of IFX and second, to evaluate the effect 
of this discontinuation on the neonatal exposure to IFX.
Design
Pregnant IBD patients using IFX were prospectively followed. In case of remission, IFX was 
discontinued prior to gestational week 30. Disease activity and complications of the resump-
tion of the treatment were evaluated. IFX levels in the cord blood were assessed and correlated 
to the interval between last infusion and delivery. 
Results
In total, 18 pregnancies in 17 IBD patients were followed; resulting in one spontaneous mis-
carriage at week 6 and 17 live births.
All twelve patients (71%) who discontinued the treatment prior gestational week 30 remained 
in remission; one patient experienced an allergic reaction to IFX at treatment resumption. Five 
patients (29%) were not in remission and received the last infusion between gestational weeks 
30 and 34. 
The cord blood was collected from 12 newborns. The mean cord blood IFX level in the patients 
who stopped IFX more than 10 weeks prior delivery was significantly lower than in the group 
with less than 10 weeks from the last infusion to delivery (2.8±SEM 1.1 µg/mL and 10±SEM 
2.3 µg/mL, respectively, p=0.02). 
conclusion
In quiescent disease, early discontinuation of infliximab during pregnancy in inflammatory 
bowel disease is safe for patients and reduces neonatal exposure to infliximab.
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IntRODUctIOn
Inflammatory bowel disease (IBD) patients are typically in their reproductive age and pro-
creation represents thus an important factor influencing the management of these patients1. 
A favourable pregnancy outcome is strongly related to a tight control of disease activity2 which 
brings up the issue of the safety of the use of the medication necessary to control the disease 
by the mothers-to-be.
In case of infliximab (IFX), a monoclonal chimeric anti-TNF antibody, short-term data from 
the safety registries and one retrospective study3-5 are available with regards to the safety of 
use during pregnancy. These registries did not reveal teratogenicity issues but the size of the 
populations included was limited and the reports were mostly retrospective. In addition, the 
exposure to IFX in majority of the patients in these studies was confined to the first trimester, 
while placental transfer of IFX starts from the second trimester6, leaving the newborn with IFX 
levels in the range of levels considered therapeutic in adults7-9. Therefore, the concerns about 
the safety of IFX use during pregnancy relate specifically to the use of this drug in the second 
and third trimester and there are very few data evaluating this specific clinical situation.
In order to limit neonatal exposure to IFX, it is currently recommended to discontinue treat-
ment around gestational week 30. This specific timing of discontinuation has been set up rather 
arbitrary, as a compromise between the concerns about the child`s exposure and the risks of 
disease flare and allergic reactions at the treatment resumption carried by the mother. We have 
shown previously, that discontinuation of the treatment in the third trimester still results in 
significant exposure of the newborn to IFX9 and therefore, in order to limit the newborn`s ex-
posure to IFX, treatment discontinuation in the second trimester should be considered. It is 
unclear whether this approach is safe for the mother and to which extent it reduces neonatal 
exposure to IFX. Therefore, the aim of this study was first, to assess the disease course dur-
ing pregnancy after IFX discontinuation and second, to evaluate whether early discontinuation 
leads to the reduction of IFX levels in newborns.
mAteRIAL AnD metHODS
Patients and treatment protocol
Between April 2006 and April 2011, IBD patients with reproductive wish or already pregnant 
were recruited through specific outpatient clinic consultation. IBD patients were referred for 
this pre-conceptional consultation by their own gastroenterologists to the Erasmus MC, a ter-
tiary referral center. The consultation was performed in a standardized manner according to 
ECCO guidelines10 by two physicians (ZZ and vdW). Patients were recruited from the region of 
South-West Holland by the physicians affiliated to the Dutch Delta IBD Study Group. 
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The patients with active reproductive wish or already pregnant using IFX were prospectively 
followed with regular bi-monthly outpatient clinic controls with clinical assessment of disease 
activity. In case of remission defined as complete absence of complaints recognized by patients 
as IBD-related and with pregnancy compatible weight gain (i.e. at least 6 to 10 kg weight gain as 
off beginning of the third trimester), IFX was discontinued prior to gestational week 30. Patients 
with unstable disease continued treatment throughout the third trimester. Disease activity and 
complications of the resumption of treatment were evaluated. For pregnancy outcomes, birth 
weight, gestational age at delivery and congenital malformations were noted.
As this approach, including assessment of infliximab levels in the newborn, represents stan-
dard care based on recommendations from different health-professional societies (AGA, ECCO), 
no specific approval by the medical ethical committee was sollicited. Pregnancy outcomes and 
cord blood levels of infliximab of three of the patients included in this cohort have been repor-
ted previously9.
Infliximab levels in the newborns` cord blood
The cord blood was collected at delivery and IFX levels were assessed by ELISA in serum from 
cord blood as described earlier9. Briefly, assay plates were coated with TNF-α and blocked with 
milk protein to prevent non-specific binding of IFX to the assay plates. Next, the plates were 
incubated with serum from peripheral blood or cord blood. To determine the absolute levels, 
a standard curve of IFX concentrations was used. After washing the serum samples, the bound 
IFX was detected using an antibody-peroxidase conjugate directed against the Fc-part of IgG1, 
followed by an enzymatic colour reaction. The assay was tested and validated using serum sam-
ples from patients receiving IFX and those who were naïve to these drugs. 
Statistical analysis
For analysis of the effect of the timing of IFX discontinuation on perinatal IFX levels, patients 
were divided into two groups. The group of late discontinuation comprised patients with the 
time from the last infusion to delivery 10 weeks and less. The IFX levels in this group were com-
pared to the group of early discontinuation with more than 10 weeks from the last infusion to 
delivery by t-test. For the correlation of gestational week of IFX discontinuation with IFX levels 
in the newborns a nonparametric Spearman`s correlation test was used.
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In total 105 female patients received (pre)conceptional counselling. Of these patients, 17 pa-
tients (16%) used IFX during pregnancy, 16 patients were on established treatment, one patient 
started the treatment with IFX due to steroid-resistant disease during pregnancy. Basic demo-
graphic characteristics are shown in Table 1.
Disease activity during pregnancy and IFX discontinuation
In total, 18 pregnancies in 17 patients (mean age 29 years, range 18 to 37; 12 with Crohn`s 
disease and 5 with ulcerative colitis) were followed. Twelve patients (71%) were in remission 
and discontinued treatment between gestational weeks 18 and 27 (average week 23), Figure 1. 
After IFX discontinuation, all 12 patients remained in remission during pregnancy. Five patients 
(29%) were not fully in remission, three of them had complaints of diarrhoea and occasional 
rectal blood loss in the last two weeks prior infliximab infusion. Two patients experienced an 
acute flare of the disease, both in the first trimester and were treated with prednisolone, one 
patient successfully. In the second patient with steroid-resistant disease, IFX treatment was ini-
tiated in the 4th month of pregnancy with good response. All these five patients with active 
disease continued the treatment throughout the third trimester and received their last infusion 
between gestational weeks 30 and 34. After delivery, all five patients improved and did not 
necessitate further therapy adjustment; one patient was able to reduce the dose of infliximab 
from 10 to 5 mg/kg.
Resumption of treatment
Fourteen patients resumed treatment after an average IFX-free interval of 18 weeks (range 
8 to 27 weeks). Nine patients started IFX within one month after delivery, 4 patients within 2 
months and one patient postponed treatment until month 3 post partum. Of these 14 patients, 
4 resumed treatment within 12 weeks (time from the last infusion of 8, 9, 9 and 11 weeks, res-
pectively). Mean follow-up after delivery was 12 months (range 2 to 25 months). During this 
follow-up, one patient experienced an allergic reaction at the resumption of IFX treatment after 
a drug holiday of 22 weeks. The allergic reaction occurred at second infusion of IFX which was 
postponed to week 11 from the first infusion due to mastitis. Two patients developed side-ef-
fects to IFX after 10 and 12 months of the treatment, respectively, and had to switch to adalimu-
mab. All patients who resumed treatment remained in remission during the follow-up.
The reasons not to resume IFX in the remaining three patients were as follows: one patient 
developed auto-immune hepatitis with liver failure post partum, with presumable etiology of 
IFX-induced hepatitis, this case has been reported elsewhere11; two patients remained stable 
and decided not to resume the treatment. All three patients had quiescent disease during the 
follow-up of 11, 12 and 13 months, respectively; one without treatment and two on monothe-
rapy with azathioprine. 
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Pregnancy outcomes 
There was one spontaneous miscarriage at week 6 and 17 live births with average gestational 
age at delivery of 39 weeks (range 32 to 42). Average birth weight was 3361 grams ranging from 
2200 to 4210. In sixteen children no congenital malformations were found. One child born to 
the mother using co-medication with methotrexate peri-conceptionally had polydactyly. This 
case was reported previously as stated in the Patients & Methods section. 
effect of the timing of IFX discontinuation on the IFX levels in the newborns
The cord blood was collected from 12 newborns. Overall mean IFX level was 6.4±SEM 1.6 µg/mL. 
The mean cord blood IFX level in the early discontinuation group was significantly lower than 
in the group with 10 or less weeks from the last infusion to delivery (2.8±SEM 1.1 µg/mL and 
10±SEM 2.3 µg/mL, respectively, p=0.02), Figure 2. The levels of IFX in the cord blood correlated 
significantly with the gestational week of IFX discontinuation (Spearman`s rho=0.71, p=0.01), 
Figure 3.
table 1. Basic demographic characteristic of pregnant infliximab-using IBD patients 
nr of patients 17
Average age (range) 29 years (18-37)
Average duration of the disease (range) 7 years (1-13)
crohn`s disease/Ulcerative colitis 12/5
co-medication
 none 6
 5-aminosalicylates 1
 thiopurines 9
 corticosteroids 2
 methotrexate* 1
Dose infliximab
 5 mg/kg every 8 weeks 14
 5 mg/kg every 6 weeks 1
 10 mg/kg every 8 weeks 1
 10 mg/kg every 6 weeks 1
*peri-conceptionally, treatment stopped immediately after pregnancy was confirmed
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Figure 1. Effect of the infliximab discontinuation during pregnancy on disease activity and 
complications at the re-treatment
*allergic reaction at the second infusion of IFX after drug holiday of 22 weeks; second infusion postponed 
to week 11 due to mastitis
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1 spontaneous 
 miscarriage 
(gestational week 6)
17 live births 
(94%)
Disease in remission?
17 pts
YES
12 pts (71%)
NO
5 pts (29%)
• no relapse
• one patient developed allergic
 reaction at the resumption
 of the treatment post partum*
• infliximab discontinued
 (gestational weeks 18 to 27)
• infliximab continued
 (till gestational weeks 30 to 34)
Figure 2. IFX levels in the cord blood are significantly reduced in the group with more than 
10 weeks time to delivery from IFX discontinuation (early discontinuation) with average cord 
blood IFX level in early discontinuation group 2.8±SEM 1.1 µg/mL vs. 10±SEM 2.3 µg/mL in late 
discontinuation group. 
           *Two-sided, unpaired t-test
      
Figure 3. The IFX levels in the cord blood positively correlate with the gestational week of the 
IFX discontinuation. Spearman`s rho=0.71, p=0.01
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DIScUSSIOn
In this study, we prospectively evaluated the impact of infliximab discontinuation during 
pregnancy on the course of inflammatory bowel disease. We found that discontinuation prior 
gestational week 30 in patients with quiescent disease is feasible and safe in terms of disease 
control. In addition, this approach significantly reduces the neonatal exposure to infliximab. 
As in all procedures related to the pregnancy, there are considerations to be made in the 
mother`s as well as child`s interest. With respect to the mother, the main concerns are disease 
control and risk of side effects at the treatment resumption after being off IFX for more than 
12 weeks. Interestingly, three patients in our cohort did not resume treatment and remained in 
remission during the remaining 11 and 13 months of the follow-up, respectively. This is in line 
with previous observations that pregnancy may in some patients modify the disease course 
with lower risk of flares in the years after pregnancy12,13. In addition, there are clear indications 
that pregnancy in general represents a specific condition down-regulating the inflammatory 
responses in order to induce transient tolerance of the foreign body of the foetus14. Thus, with 
a little exaggeration, one may think of pregnancy as ‘a natural immunomodulator’ with stabi-
lizing effect on the disease on-going for several months after delivery. With this concept, the 
question arises whether it is beneficial for the patient to resume the treatment with anti-TNF 
post partum while being in remission instead of continuing the drug holiday started during 
pregnancy and to resume the treatment only when the disease flares again. Currently, there are 
no data to favour either of the approaches but keeping in mind the risks related to long-term 
anti-TNF use this opportunity of drug holiday may seem attractive for some female IBD patients. 
In addition, as shown recently, the titers of antibodies against infliximab formed during the 
treatment decrease with the longer duration of the drug holiday and become undetectable 
within one year after cessation of the treatment15. Thus, prolonging the drug holiday might also 
be beneficial for the patient in terms of immunogenicity.
This immunogenic complication of the treatment resumption represents a second concern 
on the maternal side. We have observed one allergic reaction that could have been co-genera-
ted by a delayed administration of a second infusion at week 11. Probably, the right approach 
would be to try to minimalize the risk of allergic reaction at the treatment resumption by tight 
infusion schedule with conservation of the interval of eight weeks and by starting with an in-
duction scheme as it is also the case with the use of infliximab in general16. 
Third, another risk of the treatment resumption related also to immunogenicity is a gradual 
loss of response resulting from antibody formation against IFX17. During the mean follow-up 
of one year, we did not observe any case of loss of response, with all patients resuming the 
treatment remaining in remission. 
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Concerning the child, we found that IFX infusion ten weeks or less prior delivery led to cord 
blood drug levels considered therapeutic in adults. It has been shown that IFX can persist in the 
child for several months8, which has important consequences for the immature immune system. 
First, the vaccination with live vaccins may result in disseminated infections as documented by 
a fatal case of a disseminated BCG infection of a 3-month old baby girl born to mother treated 
with IFX during the entire pregnancy18. Therefore, the vaccination with live vaccins needs to be 
postponed in these children until the levels of IFX are negative which brings along the risk of 
contracting the infection if the child lives in an endemic community. 
Second, therapeutic IFX levels may interfere with induction of a normal antibody response to 
vaccination of non-viable antigens. Two small case series together including 10 children repor-
ted that children born with therapeutic levels of IFX had a normal antibody response to vacci-
nations with bacterial antigens19,9, but larger studies in adults showed that antibody formation 
to some viral antigen vaccins may be hampered by anti-TNF treatment20. It is unknown whether 
this is also the case for children vaccinated in the presence of IFX. 
Third, the theoretical concerns of late consequences of the early exposure of an immature im-
mune system to the modulatory effect of TNF-α blockade are, in our view, justified. The follow-
up of children born from pregnancies exposed to anti-TNF is still too short to allow firm con-
clusions on the (lack of ) oncogenic, immunogenic and allergenic potential of this interference 
of the developing immune system with a foreign protein blocking one of the main signalling 
pathways of immune cells. In addition, a long-term imprinting of the specific B cell repertoire 
by maternal antibodies has been demonstrated in mice21 which, if true for the humans as well, 
would have important consequences for the shaping of humoral immune response repertoire 
in children with intra-uterine exposure to IFX. 
Although the levels of IFX assessed in the cord blood were significantly reduced by disconti-
nuation of IFX more than 10 weeks prior delivery, they were still detectable. Thus, one must keep 
in mind that even with this approach of discontinuing IFX during the second trimester, children 
are exposed to IFX in utero and in the early postnatal period. Therefore, the next step should pro-
bably be to test the feasibility of discontinuing IFX even earlier, i.e. at the beginning of the second 
trimester, around week 16, in order to completely eliminate the early postnatal exposure to IFX. 
In conclusion, this study shows that discontinuation of IFX treatment early during pregnancy 
substantially limits postnatal exposure of the child to IFX and that this approach is safe for the 
mother in terms of disease control and risks related to resumption of the treatment. Therefore, 
keeping concerns about the early exposure to IFX related risks for the child in mind; we re-
commend considering the discontinuation of IFX treatment in patients with quiescent disease 
during the second trimester. The exact protocol of the resumption of the treatment remains to 
be determined.
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Chapter 10
Pregnancy and AntiTNF Use: Safety is not yet Assured
Christine J van der Woude&Zuzana Zelinkova
Adapted from inflamm Bowel dis Monit 2011; 12(2):55-56
IBD typically affect patients in their reproductive years and the reproductive issues represent 
an important concern to female IBD patients1,2. IBD patients choose to remain childless more 
often than non-IBD controls1,3,4, mostly owing to the fear of the side-effects of the medication 
on the unborn child1.
The decision to continue the medication that is maintaining these chronically ill patients in 
remission during the peri-conceptional period and pregnancy is difficult as the data on some 
drugs used in IBD in this setting are limited, and evidence-based counseling is scarcely possible. 
It should be emphasized that a quiescent disease state is key to a favorable pregnancy outco-
me; therefore, a careful appreciation of the safety of the medication necessary to maintain the 
remission is crucial in the management of IBD patients with reproductive intentions5,6. The data 
gathered thus far suggest that most of the drugs used to maintain IBD in remission are safe 
with regards to teratogenicity, except for methotrexate. However, the situation regarding the 
use of anti-TNF agents during pregnancy is more complicated compared with the use of small 
molecules. 
Of the various anti-TNF agents available in IBD, infliximab has been used the longest; thus, 
most experience with anti-TNF use during pregnancy is with this biologic. Short-term data have 
found no important teratogenicity issues but it is important to emphasize that the size of the 
studied population is small, the reports are mostly retrospective, and the majority of children 
born from these pregnancies were exposed to infliximab only during the first trimester7,8.
Infliximab belongs to the immunoglobulin G (IgG) class and, as such, has a functional Fc tail. 
Therefore, its kinetics is likely to be governed by the neonatal Fc receptor (FcRn), as is the case 
for natural IgG9. In general, IgGs are sequestered by endothelial cells through binding to intra-
cellularly expressed FcRn and then shuttled back to the extracellular milieu. By protecting the 
antibody from catabolism by this mechanism, the lifetime of the antibody is increased10. During 
pregnancy, maternal IgG antibodies cross the placenta in the same way and this transfer begins 
in the second trimester and reaches its maximum towards the end of the pregnancy11. It has 
been shown that levels of infliximab measured in the cord blood of children born to mothers 
exposed to anti-TNF in the second and third trimester exceed the maternal infliximab levels up 
to four-fold, depending on the period between the last infusion and delivery12,13. In addition, 
detectable levels of infliximab in children persist up to 7 months of life, which is not surprising 
given the FcRn-mediated efficient turnover of IgG during the first months of life12. Thus, inflixi-
mab seems to cross the placenta the same way as natural maternal IgG, and children born to 
mothers treated with infliximab during the second and third trimester are exposed to this agent 
in utero and during their first months of life. Concerns about the long-term effects of this ex-
posure are, in our view, substantial, and cover the whole range of potential problems resulting 
from TNF-α blockade in the early stages of the immune system development, such as infecti-
ons, allergies, autoimmune disorders, and malignancies. Reports on the follow-up of children 
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exposed to anti-TNFs in their first months of life are limited to the first year of life, which is too 
short to exclude these kinds of long-term complications.
Therefore, in the current scenario of a lack of long-term follow-up data, the limitation of pla-
cental transfer of infliximab by treatment discontinuation during pregnancy might be an op-
tion in patients with stable disease. Currently, it is recommended to discontinue the treatment 
with infliximab at around week 32. However, in our case series of four patients, we have docu-
mented that this approach still leaves the children with significant levels of infliximab measu-
red in cord blood13. In order to limit the placental transfer to zero, the discontinuation of the 
treatment should take place much earlier, probably prior to gestational week 24 (Zelinkova et 
al., unpublished data). Therefore, we suggest limiting the use of infliximab during pregnancy 
to only the first two trimesters. This approach has been demonstrated to be feasible and safe in 
terms of disease control and no allergic reactions have been observed at the resumption of the 
treatment after a period of more than 12 weeks14,15.
For adalimumab, data are even more limited. Again, in the registry data available so far, no 
teratogenicity issues have been observed; however, as expected based on the molecular struc-
ture of adalimumab with a functional Fc component, placental transfer has been documen-
ted16,17. The pharmacokinetics of infliximab and adalimumab differ substantially, with different 
dosing regimens and biological half-times. Therefore, no advice can be given on the timing of 
discontinuation of anti-TNF agents in general; data for each agent need to be collected in order 
to make specific estimations. Currently, there are no such data available for adalimumab and 
therefore at this time no evidence-based recommendations can be made with regards to the 
timing of its discontinuation during pregnancy.
In conclusion, the use of anti-TNF agents in the periconceptional period and during pregnan-
cy does not seem to carry a risk of congenital malformations. However, given the basic phar-
macodynamic and pharmacokinetic properties of anti-TNF agents, the simple demonstration of 
non-teratogenicity is not sufficient to consider these agents as safe for use by mothers-to-be. 
The major concern regarding the use of anti-TNF agents during pregnancy is their placental 
transfer leading to therapeutic levels in the newborns. This early exposure of the immature 
immune system to the potent effects of TNF-α blockade might result in as yet unpredictable 
long-term complications; therefore, in patients with quiescent disease, these agents should be 
discontinued early in the pregnancy in order to limit this exposure to the lowest possible level. 
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Chapter 11
Summary 
Nederlandse Samenvatting
General Discussion 
SUmmARY
Central to this thesis is the notion that inflammatory bowel disease (IBD) is different between 
females and males in important ways influencing genetics and transmission to the next 
generation, manifestation of the disorder, perception of disease severity whereas the different 
roles of males and females in human reproduction has important consequences for treatment. A 
theoretical foundation for the notion that IBD has important gender and/or sex specific aspects 
is provided in chapter 1, which includes apart from clinical intuition, an extensive review of the 
existing reports in this field, and an appreciation of the physiological differences between the 
immune systems of males and females. The aim of this thesis is to explore these gender and/
or sex specific aspects over the entire width of the field, with the main objective to provide a 
comprehensive study of all aspects involved.
First, in a patient empowerment study (chapter 2), an assessment of the differences between 
men and women in the perception of health-related quality of life (HRQOL) is provided that 
confirmed previous observations of a lower HRQOL in women in general. The additional value 
of this study relies in its patient empowerment character with selected questions generated by 
the patients themselves, enabling a different view on this issue compared with studies using 
standardized questionnaires. This design enabled us to further characterize the respective 
domains in which men and women with IBD report different concerns. More specifically, as 
a result of the disease, women feel unable to meet their expectations with regards to study/
work, household, partnership, and parenting. In order to translate these observations into a 
personalized approach used in everyday practice, these gender-specific differences cannot 
be ignored when an overall assessment of patients’ well-being is attempted and thus prompt 
the development of a gender-specific quality of life questionnaire. In addition, the root causes 
leading to these gender-specific differences should be further explored in detail taking into 
account both social (i.e. gender-related) and biological (sex-determined) determinants possibly 
involved. Together with the more theoretical framework provided in chapter 1, this part of the 
thesis makes likely that gender and/or sex is an important factor when considering IBD the 
consequences of this phenomenon are subsequently explored. 
Biological factors underlying sexual dimorphic disease presentation are studied in part II 
of this thesis. In particular, in chapter 3 the issue of female predominance in familial IBD is 
addressed by studying the imprinting pattern in families where both the parent and the child/
children are affected. In this study, we show that female predominance in familial IBD is at least 
partially due to maternal imprinting, a phenomenon with an unclear mechanism, suggesting 
the existence of epigenetic rather than genetic factors in sex-specific IBD pathogenesis. The 
existence of this sex-specific pathogenicity suggested by maternal imprinting might have 
important consequences for the understanding of the disease genesis itself and necessitates 
further exploration. The role of sex hormones on one side, as well as the direct involvement of 
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X-chromosome abnormalities on the other side, are areas worth investigating further in order 
to define in detail how sex influences the immune responses leading to IBD and may well have 
consequences for other diseases as well.
chapter 4 deals with the sexual dimorphism of immune responses that is not related only 
to disease pathogenesis, but also presumably influences therapy outcomes once the disease 
is manifest. More specifically, we show that female patients are at higher risk of developing 
allergic reactions to treatment with monoclonal antibodies against tumour necrosis factor 
alpha (anti-TNF), which in turn limits the portfolio of treatment modalities available for female 
IBD patients. This female-specific increased risk of anti-TNF immunogenicity provides evidence 
for the existence of sex-related differences in immune regulation and thus has important 
consequences for the management of immune-mediated diseases, females requiring probably 
a more aggressive approach. Therapeutic possibilities in the field of IBD are still very limited; 
therefore, maintaining the ability to continue effective treatment by preventing adverse drug 
reactions is crucial for individual patients. Therefore, further research in this field on options 
to limit these reactions in females through sex-specific therapeutic approaches and the 
mechanism of this dimorphism is urgently needed. 
The third part of this thesis is dedicated to a specific area of gender research; reproduction. 
As shown in chapter 5, reproductive wish represents an important factor interfering with the 
management of IBD patients. Two thirds of IBD patients with active reproductive wish use a 
medication with an unclear safety profile in this setting. In addition, one third of these patients 
need a change in their therapeutic approach because their medication is contra-indicated 
for the mothers/fathers-to-be or because of uncontrolled disease. Thus, the physicians caring 
for IBD patients should take active role in providing counselling for these patients in order 
to limit the possible complications resulting from negative impact of the medication and/or 
uncontrolled disease on the unborn child. On the other hand, data on the safety of particular 
medications used peri-conceptionally and during pregnancy and lactation are limited and both, 
the researchers and clinicians need to be creative in their attempts to safeguard the safety of a 
particular medication use during procreation. Such an approach is demonstrated on the case 
of azathioprine, one of the agents used for the maintenance of IBD. This drug has questionable 
safety during lactation. In chapter 6, we show that based on drug levels monitored in the 
newborns, azathioprine can be used safely during lactation.
Of all the drugs used in IBD, the use of anti-TNF agents during the peri-conceptional period 
and pregnancy is the most complicated issue given the lack of data and specificities on the 
pharmacokinetics of IgG class antibodies to which these agents belong. In chapter 7, it is 
demonstrated that the use of one of the anti-TNF agents, infliximab, beyond the second 
trimester leads to significant placental transfer of the agent, with neonatal exposure to levels 
of this agent that would be considered therapeutic in adults. The concerns about the potential 
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consequences of this early exposure of an immature immune system to powerful blockade of 
one of the key signalling pathways in the immune system are substantial, as summarized in 
chapter 10. Therefore, in order to limit exposure, early discontinuation of infliximab during 
pregnancy is recommended. However, no data on the safety of this approach for the mother 
are available. In chapter 9, the outcomes are shown of the prospectively-followed pregnancies 
of mothers using infliximab who discontinued treatment in a controlled manner during 
the second trimester. We demonstrate that in the case of quiescent disease, discontinuing 
infliximab during the second trimester does not lead to higher risk of relapse and/or adverse 
reactions when treatment is resumed, and is safe for the mother. Additionally, this approach 
helps significantly reduce neonatal exposure to infliximab. These observations provide the 
basis for recommending infliximab for use during pregnancy in chapter 10. 
The use of anti-TNF agents by male patients who wish to procreate represents an important 
and controversial issue as well and available data on this subject are even more limited than for 
female patients. In the case of another anti-TNF agent, adalimumab, the data on its safety for 
fathers-to-be are lacking. To address the need for data on this issue, a prospective assessment 
of the influence of adalimumab on semen composition was performed and pregnancies 
with indirect exposure to adalimumab in the outpatient clinic population were identified 
retrospectively. The results of this study, which showed no influence of adalimumab on semen 
composition and favourable pregnancy outcomes of men treated with adalimumab, are 
discussed in chapter 8. 
In summary, differences based on gender and/or sex of various aspects of IBD were assessed. 
Surprisingly, in an attempt to achieve the original aim, i.e. to identify issues specific to men and 
women, respectively, we ended by accumulating evidence almost exclusively for female issues. 
The results reported in this thesis support the idea that male and female IBD is not completely 
the same disease, maybe with the most dramatic differences when considering reproduction, 
but also regarding the quality of life, disease pathogenesis, and complications of therapy. Thus, 
using slightly exaggerated philosophical jargon, based on the observations gathered in this 
hypothesis-generating research, further basic and clinical research in IBD is called for to address 
the under-investigated notion of an IBD `du deuxième sexe`. 
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neDeRLAnDSe SAmenVAttInG
In dit proefschrift wordt nader ingegaan op de invloed die het geslacht kan hebben op het 
verloop  van inflammatoire darmziekten. Het overzicht van de huidige literatuur in Hoofdstuk 1 
geeft onderbouwing voor de keuze van de in dit proefschrift bestudeerde aspecten ten aanzien 
van de relatie geslacht en IBD.
Hoofdstuk 2 laat de verschillen zien in kwaliteit van leven tussen mannelijke en vrouwelijke 
IBD patienten. Het onderzoek is opgezet als een `patient empowerment` studie: patiënten 
hebben de gebruikte vragenlijst zelf ontwikkeld. We tonen aan dat vrouwelijke IBD patiënten 
significant meer negatieve invloed van de ziekte op hun kwaliteit van leven ervaren vergeleken 
met mannelijke IBD patiënten. Dit is  in overeenstemming met eerder gepubliceerde studies. 
Deze kwaliteit van leven bij vrouwen wordt vooral negatief beïnvloedt door beperkingen 
op het terrein van studie/werk, huishoudelijke bezigheden, relatie met de partner en het 
moederschap. Wij beschrijven in deze studie voor het eerst dat geslachtsgerelateerde 
verschillen in deze domeinen bepalend zijn voor de kwaliteit van leven van IBD patiënten. Onze 
conclusie is dan ook dat het bepalen van de kwaliteit van leven bij IBD patiënten moet worden 
aangepast door introductie van geslachts specifieke domeinen. Daarnaast moet de aard van de 
ziekte-gerelateerde verlaagde kwaliteit van leven bij vrouwen verder onderzocht worden om 
te kunnen bepalen of deze puur door socio-economische factoren wordt beïnvloed (gender-
related) dan wel of door het verschil is te verklaren in de biologie van vrouwen en mannen.
Deze laatste vraag is verder bestudeerd in het tweede gedeelte van dit proefschrift (Sex, 
Hoofdstuk 3 en 4). In Hoofdstuk 3 laten we zien dat in families waarbij IBD voorkomt bij 
ouder(s) en kind(eren), dit significant vaker het geval is als er een IBD moeder is vergeleken 
met families met een IBD vader. Deze vinding suggereert dat er voor de overerving van IBD 
de klassieke Mendelien regels niet gelden. Waarschijnlijk spelen epigenetische factoren een 
belangrijke rol in de overerving bij IBD.  Het is bekend dat IBD vrouwen een meer gecompliceerd 
beloop van de ziekte hebben in vergelijking met IBD mannen. Of hierbij dezelfde epigenetische 
factoren die ook een rol spelen in het ontstaan van de ziekte belangrijk zijn moet uit toekomstig 
onderzoek blijken. 
Specifieke ziekte karakteristieken bij vrouwen, zoals een meer gecompliceerd beloop en het 
vaker voorkomen van extra-intestinale manifestaties bij IBD vrouwen duiden, samen met onze 
resultaten beschreven in Hoofdstuk 3, op  vrouw specifieke pathogenetische mechanismen 
wat in theorie ook invloed zou kunnen hebben op de effectiviteit en bijwerkingen van de 
medicamenteuze behandeling. Deze geslachtsspecifieke uitkomsten van therapie zijn verder 
onderzocht in Hoofdstuk 4. In dit hoofdstuk wordt beschreven dat er geslachtsspecifieke 
verschillen zijn in het bijwerkingpatroon van medicatie voorgeschreven voor de behandeling 
van IBD. Het blijkt dat vrouwen vaker allergische reacties vertonen op tumor necrosis factor 
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alpha inhiberende medicatie (anti-TNF). Deze reacties  leiden uiteindelijk tot het staken van deze 
medicatie. Hierdoor worden de therapeutische mogelijkheden voor IBD vrouwen significant 
gelimiteerd. Om de therapie effectiviteit te maximaliseren is het dus van belang onze bevinding 
in een prospectief onderzoek te bestuderen. Bij bevestiging van onze resultaten zal vervolgens 
een vrouwspecifieke strategie voor de behandeling van IBD ontwikkeld kunnen worden.
IBD en reproductie is onderdeel van het derde gedeelte van dit proefschrift. In Hoofdstuk 5 
wordt beschreven dat kinderwens in deze groep patiënten van invloed is op de therapeutische 
beslissingen. Echter deze beslissingen zijn soms moeilijk te nemen wegens het ontbreken 
van voldoende informatie over de veiligheid van het gebruik van bepaalde medicatie tijdens 
bevruchting, zwangerschap en borstvoeding. In Hoofdstuk 6 worden eerste resultaten getoond 
van monitoring van kinderen die borstvoeding krijgen van IBD moeders die azathioprine 
gebruiken. Wij vonden bij deze kinderen bij volledige borstvoeding onmeetbare azathioprine 
spiegels. 
Veel informatie is er vooral niet over de veiligheid van het gebruik van anti-TNF tijdens 
conceptie en zwangerschap. Hoofdstuk 7 laat zien dat er duidelijke blootstelling is van de 
kinderen geboren van IBD moeders die tijdens zwangerschap behandeld zijn met een van deze 
middelen, infliximab. Onze metingen in het navelstrengbloed tonen aan dat deze kinderen 
blootgesteld worden aan significante hoeveelheden infliximab. Om deze blootstelling te 
beperken, zou infliximab tijdig tijdens zwangerschap gestopt moeten worden. Het is echter 
belangrijk voor de uitkomst van het kind om de ziekte tijdens zwangerschap in remissie te 
houden. In Hoofdstuk 9 laten we zien dat bij vrouwen met een rustige IBD het veilig is om 
infliximab in de tweede trimester te staken en dat deze aanpak significant de blootstelling van 
kinderen aan dit middel verminderd. Samenvattende opmerkingen met overzicht van alle tot 
nu toe gepubliceerde data over het gebruik van biologicals tijdens zwangerschap bij patiënten 
met IBD en het voorstel van een behandelschema zijn in Hoofdstuk 10 beschreven. 
De informatie over de veiligheid van het gebruik van biologische middelen door mannen 
met kinderwens is nog beperkter. Slechts case series zijn gepubliceerd voor infliximab en data 
over het effect van adalimumab, ontbreken geheel. Hoofdstuk 8 bevat een analyse van de 
veranderingen in het zaad bij mannen met IBD die tijdens de behandeling met adalimumab 
optreden. Uit onze analyse blijkt dat adalimumab geen of nauwelijks effect heeft op de 
samenstelling van het zaad, echter zal nog verder onderzoek moeten tonen of er ook geen 
DNA schade optreedt. 
Samenvattend, de resultaten van de studies beschreven in dit proefschrift laten zien dat het 
geslacht een belangrijke rol speelt bij inflammatoire darmziekten. Dit geldt voor verschillende 
aspecten die effect hebben op de  pathogenese, ziekte beloop en de therapeutische strategie 
die significant beperkt is in de periode van bevruchting, zwangerschap en borstvoeding. 
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Onverwacht is dat ook in de reproductie niet gerelateerde aspecten vooral vrouwelijke factoren 
naar voren komen die van invloed zijn. Om op maat gemaakt therapeutische strategie te 
ontwikkelen voor vrouwen en mannen is verder onderzoek noodzakelijk om de biologische 
basis voor deze geslachtgerelateerde verschillen te definiëren.
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GeneRAL DIScUSSIOn
In the recent years, a significant effort has been invested in the research on the contribution 
of gender/sex to human health. This effort resulted in a publication explosion of the papers 
dealing with the sex differences in various areas of (bio)medical research and several new 
journals have appeared devoted specially to gender/sex-related issues. 
In general, new insights have been gained into the role of gender/sex in physiological and 
pathophysiological processes such as pain perception, immune responses, metabolism and 
pharmacokinetics and pharmacodynamics. In addition, in several areas of clinical medicine, the 
specific contribution of the gender/sex to the disease presentation, pathogenesis, and course 
as well as therapy outcomes has been recognized. However, despite of all this considerable 
development in the field of gender-related research, the concept of gender-specific medicine 
is hardly visible in clinical practice. 
The implementation of the results of gender/sex-related studies in the clinical practice is 
hampered by several factors related to specific methodological issues of this area of research. 
From the public health care point of view, establishing of the concept of gender-specific 
care needs to be justified by clear pathogenetic explanation of a given gender/sex-related 
phenomenon. Without understanding the underlying mechanism by which gender/sex 
contributes to the respective pathogenetic processes, no gender-specific interventions can 
be successful. Yet, for most of the clinically observed differences between male and female 
patients, the explanation of molecular mechanism is lacking.
Most of the studies dealing with the sexual dimorphism in clinical medicine are descriptive 
population studies. In these studies, specific health outcomes, such as health-related quality 
of life, complicated disease course or unfavourable therapy outcomes are studied in male and 
female patients, respectively; and relative risks for each particular outcome are calculated for 
both sexes. The observed differences can be determined by both, gender- and sex-related 
factors. Gender-related factors are derived from societal and cultural context in which women 
and men deal with the burden of the disease, are exposed to different environmental factors, 
have gender-specific socio-economic status and occupations. Sex-determined differences 
in various health outcomes result from sex-specific biological processes, e.g. X-chromosome 
abnormalities, sex-steroids sensitive physiology of. Once the difference between male and 
female patients for a particular health outcome is described and, ideally, validated in several 
independent populations the attribution to gender-related and/or sex-determined determinant 
represents a crucial step for further mechanistic research. In addition, development of 
proper therapeutic intervention is also highly dependent on the recognition of the relative 
contribution of gender and sex to the particular health outcome. The distinction between 
gender relations and sex-linked biology is, however, not always methodologically possible as 
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they can represent co-founder for each other or, depending on a particular study context, can 
act as sole, independent or synergistic determinants. Therefore, for the creation of gender- and 
sex-specific concept of a particular disease, a description of one isolated phenomenon is not 
sufficient. Instead, the evidence gained from comprehensive studies dealing respectively with 
the role of gender/sex in the pathogenesis, disease presentation, course and therapy outcome 
must be integrated in the formulation of the hypothesis that will further be explored in the 
mechanistic studies. In the present work, we showed that female IBD patients have a lower 
health-related quality of life (HRQOL). By analysing the differences between men and women 
with IBD in the perception of the respective domains determining HRQOL we found that the 
lower HRQOL in women was related to societal factors as well as to biologically-determined 
restrictions in physical performance. In further studies on sex-specific genesis and therapy 
outcome of IBD, we found additional arguments for the biological contribution of female sex 
to lower HRQOL and previously reported differences in the disease phenotype between male 
and female patients. Thus, by studying these at the first sight unrelated subjects, we aimed at 
proceeding towards an integrated view on the gender and sex-specific concept of IBD. 
One of the specific areas greatly influenced by gender and sex is related to reproduction. 
Family planning of chronically ill patients represents an important factor interfering with 
the medical management of these mothers- and fathers-to-be. Despite the obvious need for 
evidence-based approach in this specific clinical setting, the available body of evidence in 
this area is extremely limited. For the use of medication during conception and pregnancy, 
compromise between the risks of the medication versus the risks of uncontrolled disease for 
the unborn child is sought. The final opinion on the medication safety in this setting is formed 
based on the animal studies and data from pregnancy registries and case-control studies. 
Animal models have a low predictive value for the teratogenicity in human situation and the 
pregnancy registries and case-control studies are prone to important selection and reporting 
bias. In addition, considering the incidence of chronic disorders among females in reproductive 
age, an adequate sample size in order to detect unfavourable effects can hardly be achieved. 
On the other hand, in this situation of the limited possibilities to gather quality data allowing 
development of evidence-based guidelines, risks for the mother-to-be and for the unborn 
child can both be minimalized using different methodological approach. First, good quality 
pharmacokinetic studies, although performed on the limited number of patients can provide 
important tool to safeguard the safety of the medication use during pregnancy for the child. 
In the part III (Reproduction) of this thesis, we show the results of such an approach. By using 
the drug monitoring in children born to mothers with IBD treated with immunosuppressive 
and biological therapy during pregnancy and lactation, we were able to minimalize the risk of 
the exposure of the (unborn) child to these drugs. Second, in immune-mediated disease, such 
as IBD, the immunological changes related to the pregnancy may result in a modulation of the 
disease course and therapy response. Therefore, the need for the immune suppression during 
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pregnancy and in the early post partum period might substantially differ from the pre-pregnancy 
state. In this work, we show that it is possible to safely discontinue the treatment with one 
biological agent, infliximab, minimizing thereby the exposure of the unborn child to this drug. 
In addition, the patients were able to discontinue the treatment for an unusually long period 
which suggests that the changes in immune response induced by pregnancy might extent 
their effect beyond the gestational period. Concluding, a proper use of the pharmacological 
armamentarium and understanding the specificities of the disease course during pregnancy 
can provide a valuable input for the development of therapeutic approach for pregnant women 
with chronic illness. In addition, in immune-mediated disease, the immunological changes 
during pregnancy and their impact on the disease course need to be evaluated as they may 
influence the management of the patient beyond the pregnancy as well.
In conclusion, in order to create a personalized medicine with gender-specific approach 
as its integrated part, the relative contribution of gender and sex to the observed male- and 
female –specificities of a particular health outcome needs to be determined. For this purpose, 
multidisciplinary research that will analyse the role the gender/sex play in all aspects of 
particular disease, including the management of the pregnant patient, is necessary.     
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Dankwoord
In 2003 kwam ik naar Nederland op zoek naar `adventures of expat life`. Ik hoopte dat ik 
misschien op een dag de gelegenheid zou krijgen om mee te mogen doen in de wereld van 
translationeel onderzoek op het gebied van IBD dat in dit land zo sterk is. Deze luxe werd mij ook 
aangeboden en ik heb elke dag kunnen genieten van de combinatie van onderzoek en kliniek. 
Dit proefschrift is een verslaglegging van mijn nederlandse en medisch-wetenschappelijke 
avontuur wat zonder de hulp van veel mensen niet mogelijk zou zijn geweest; slechts een 
aantal van deze mensen zal ik hier persoonlijk kunnen bedanken. 
Allereerst mijn promotoren prof. Ernst J. Kuipers en prof. Maikel P. Peppelenbosch. 
Beste Ernst, je hebt me altijd je vertrouwen gegeven en mij ondersteund in al mijn klinische 
en wetenschappelijke ondernemingen. Jouw bijdrage aan alle papers die we tot nu toe samen 
hebben gepubliceerd is priceless. Het lezen van een door jouw gecorrigeerde paper met je 
scherpe blik en constructieve opmerkingen was altijd een zeer plezierige leermoment voor mij. 
Daarnaast was je ook altijd bereid om een klinisch probleem met mij door te nemen wanneer 
ik er met mijn geringe klinische ervaring in de MDL er niet uit kon komen. Bedankt voor alles, 
zonder jouw was mijn nederlandse escapade heel anders gelopen.
Beste Maikel, je was een van de eerste mensen die ik in wetenschappelijk Nederland heb 
ontmoet. Jouw beroemde experiment schema`s geschetst op servetjes van de koffiekamer 
met koffievlekken erop waren de meest belangrijke onderdelen van mijn labjournal toen ik 
als `zoeker` nog in het amc bezig was. De ontelbare vrijdagavond biertjes hebben een stevige 
basis gelegd voor onze latere samenwerking in het Erasmus MC waar dit boekje tot stand is 
gekomen. Jouw enthousiasme en energie zijn onuitputtelijk en aanstekelijk. Na een discussie 
met jouw kan je niet anders dan een experiment, artikel of subsidieaanvraag direct afmaken 
ook al is het vrijdagavond en heb je de volgende dag weekend dienst. Bedankt Maikel voor 
deze bijzondere momenten waarbij we ook altijd veel hebben kunnen lachen.
Dan mijn co-promoter, dr. C Janneke van der Woude. Beste Janneke, hier komt het, onderzoek 
over ‘die vrouwen’, het idee dat ons door de jaren heen heeft achtervolgd. Ik hoop dat jij de 
afgelopen jaren net zoveel plezier aan dit onderzoek hebt beleefd als ik. Het was vaak moeilijk 
om niet op te geven toen we weer voor de zoveelste keer van onze peers hoorde dat het idee 
te feministisch, oninteressant of niet relevant was. Jouw lef en doorzettingsvermogen hebben 
mij geholpen in deze kleine strijd tegen les idées reçues. Bedankt Janneke, voor alle zakelijke 
maar ook persoonlijke discussies die we nog steeds vaak houden; ik hoop dat het ook zo blijft 
ondanks de afstand.
Geachte commissieleden, ik wil jullie graag bedanken voor jullie bereidheid om mijn 
proefschrift kritisch te beoordelen. 
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Dit boekje is tot stand gekomen tijdens mijn opleiding tot MDL-arts. In de jaren van mijn 
opleiding hebben veel mensen om me heen bijgedragen aan mijn gedachtenvorming over 
bepaalde onderwerpen die beschreven staan in dit proefschrift. De informele discussies met 
de stafleden en assistenten in de koffiekamer of het verslagruimte van de endoscopie hebben 
me vaak geïnspireerd om mijn onderzoeksvraag beter te formuleren. Naast deze genoemde 
brainstorm sessies was het een zeer plezierige tijd waarbij ik ook nog op jullie steun kon 
rekenen bij het regelen van de lastige logistiek van veel van mijn studies. Hiervoor veel dank 
aan alle stafleden en assistenten.
Mijn paranimfen, Rachel en Claudia. Ik ben zo blij dat jullie deze taak hebben geaccepteerd! 
Ik neem hier de gelegenheid om jullie te bedanken niet alleen maar voor jullie steun bij mijn 
promotietraject maar ook voor alle gezellige koffies, biertjes, uitjes en kletsavonden die we 
tijdens onze opleidingstijd samen hebben doorgebracht. Ik miss jullie en hoop echt dat we 
binnenkort weer samen gaan borrelen, waar dan ook!
Niks in dit boekje was mogelijk geweest zonder onze geweldige poli assistenten en de 
verpleegkundigen op de afdelingen endoscopie, dagbehandeling en verpleegafdeling. Jullie 
waren altijd bereid om die rare aanvragen van Zuzana te accepteren voor weer een scopie bij 
een zwangere die ook nog dezelfde dag moest, of een extra buis bloed af te nemen, of even 
een opname te regelen. En al die poli’s die altijd uitliepen en de ontelbare telefoontjes van 
patiënten die door jullie professioneel beantwoord werden. En dit allemaal met een glimlach. 
Bedankt voor deze zeer prettige samenwerking!
In het bijzonder wil ik mijn sparingpartners van de kinder MDL bedanken, dr. Lissy de Ridder 
en prof. Hankje Escher. Beste Lissy en Hankje, het was altijd een genoegen om met jullie 
medische en wetenschappelijke maar ook persoonlijke discussies te houden. We hebben los 
van dit boekje ook veel ander werk samen gedaan. Ik heb van deze samenwerking veel geleerd 
en er bovendiener ook veel plezier aan beleefd. Nogmaals bedankt, ik mis jullie!
Tijdens het tot stand komen van dit boekje is er een geweldig initiatief ontwikkeld, 
The Dutch Delta IBD group. Zonder de inzet van alle deelnemers waren de studies naar de 
zwangerschapsuitkomsten bij de behandeling met antiTNF niet mogelijk geweest. Bedankt, 
iedereen voor jullie actieve bijdrage en ook jullie vertrouwen. 
Dit brengt me bij de patiënten. Heel veel dank aan alle patiënten die vertrouwen in ons 
hadden en actief mee hebben gewerkt aan onze studies. Zonder jullie bereidheid om mee te 
werken aan het onderzoek was onze huidige kennis veel beperkter geweest.
Een bijzondere positie in dit bedanklijstje is voor onze IBD onderzoeksgroep zowel de 
klinische onderzoekers als de onderzoekers op het lab. Lauran, Alison, Cheima, Jasper, Hans, 
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Ayala, Evelien, Veerle, Yi en Judith, jullie hebben een enorme bijdrage geleverd aan dit boekje 
door jullie kritische opmerkingen bij onze meetings maar ook praktisch door jullie hulp bij de 
logistiek van de studies. Speciaal dank aan Colin, bedankt voor al je werk met de infliximab 
ELISA`s en actieve input bij het analyseren van de resultaten. Hierbij hoort ook een speciale 
dank aan Hanneke van Vuuren en Buddy Roovers voor de organisatie en het keurig verwerken 
van de navelstrengsamples.
De administratie is nooit mijn sterke punt geweest. Dat deze promotie eindelijk plaats vindt, 
mijn diplomas evaluatie rond is, alle formulieren op tijd zijn ingeleverd en het boekje in de 
brievenbus van iedereen beland is, daarvoor hoort mijn bijzondere dank aan Leonie. Bedankt 
voor alles Leonie, je bent superefficient en georganiseerd, zonder jouw was dit mij nooit 
gelukt.
En dan last but not least, onze bijzondere partners van de afdelingen Andrologie en 
Gynecologie. Dr. G.R. Dohle en prof. dr. E.A.P. Steegers, bedankt voor jullie steun bij de zorg voor 
onze IBD patiënten met een kinderwens in de dagelijkse praktijk. 
Dan is er nog een groep mensen die niet direct aan dit boekje hebben bijgedragen maar wel 
bepalend zijn geweest voor mijn Nederlandse avontuur. Als eerste prof. Sander J. van Deventer 
en prof. Daan W. Hommes. Beste Sander en Daan, wanneer jullie mij niet hadden aangenomen 
in het AMClab was er waarschijnlijk niks van dit boekje tot stand gekomen. De twee jaren op het 
lab in het AMC waren een fantastische tijd voor mij. Ik hoop ook dat hetgeen wat ik van jullie 
heb mogen leren ook tot uiting is gekomen in dit proefschrift.
Dan wil ik nog in het bijzonder een andere inmiddels ook ex-amc-er bedanken, dr. Pieter C 
Stokkers. Beste Pieter, de IBD-ology wordt nog uitgewerkt en ik blijf je erbij betrokken houden, 
of je dat wil of niet! Bedankt voor het meedenken, de brainstormsessies maar vooral gezelligheid 
die je overal mee naartoe brengt.
And then the expat group, I feel that all the negative aspects of globalisation have been 
compensated by the fact that it brought you guys into my life. Sharon, Rob, Carlos, Megan, and 
(not so expats) Arjan and Oliver thanks for the great time we had and still have together. 
A nakoniec moja malá rodinka, Meťko a Oli. Podľa starých Egypťanov je najväčším šťastím 
muža mať ženu peknú, milú a múdru. Najväčším šťastím ženy je... mať vás.
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